|
|
||||
|
|
|
|
|
|
|
|||||
|
   
|
|
|
John M. Pellock, M.D. 307 College Street Email:jpellock@hsc.vcu.edu Licensed in the States of:Missouri, New Jersey, New York, Maryland
and Virginia (#0101029700) Johns Hopkins University, Baltimore, Maryland 1961 to 1965 (B.A.) Commissioned Ensign, United States Naval Reserve, March 1968 Chairman, Division of Child Neurology, Medical College of Virginia
of Virginia Commonwealth University, 1995- Chairman, Division of Child Neurology, Medical College of Virginia
of Virginia Commonwealth University, 1995- Membership - Scientific,
Honorary, and Professional Societies
American Academy of Neurology, Fellow Major Committees Memberships in Community
Organizations American Academy of Pediatrics Residency Fellowship, 1972 Significant Scholarly Research
Research:Clinical development of new antiepileptic drugs in children
and adults. Antiepileptic drug utilization and toxicity in children. Childhood
epilepsy. Effects of anticonvulsant on the fetus.
Principal Investigator, B6 determination on INH treated children,
Virginia Lung Association, 1972-1974 Investigator (Neurological Assessments) Bilirubin study, NIH,
Harold Maurer, M.D., P.I., 1979-1981 Principal Investigator, Multicenter Controlled Study of Cinromide
(BW122U) in outpatient with the Lennox-Gastaut Syndrome, Burroughs Wellcome
Company, 1980-1981 Principal Investigator, Antiepileptic Drug Development Program
NIH-NINCDS, Master Agreement, 1981; Renewed, 1984 Principal Investigator, Multicenter Open Study of Cinromide (BW122U)
in outpatient with the Lennox-Gastaut Syndrome. Burroughs-Wellcome Company,
1981-1982 Principal Investigator, Multicenter double-blind single oral dose
study of Ibuprofen, Acetaminophen and Placebo in the treatment of pediatric
patients with postoperative pain, Protocol BPI 304-2, Boots Pharmaceuticals,
Inc. 2/84 Principal Investigator, Tegretol vs. Phenytoin in epileptic children
under six years of age, Protocol 25, Ciba-Geigy 4/84-6/86 Principal Investigator, Acute Dose Safety and Pharmacokinetics
study of BW430C and Placebo in Epileptic Patients. Burroughs Wellcome Company,
12/84-3/85 (120 and 240 mg.) Extended study to 360 and 480 mg. 4/85 Principal Investigator, Pilot Study of Fluzinamide (AHR-8559)
in absence seizures, Protocol 1701, A.H. Robins, 11/84 Principal Investigator, Effect of Antiepileptic Therapy on Cognition,
Tegretol protocol 06, Ciba-Geigy, 1/85 to 3/87 Principal Investigator, Comparative Bioavailability and Pharmacokinetics
of Carbamazepine (Tegretol) Tablets and Suspension. Ciba-Geigy 5/85-5/86 Principal Investigator, Chronic Dose Tolerance of Lamotrigine
and Placebo in Epileptic Patients. Protocol 03. Burroughs Wellcome Company,
11/85-6/86 Principal Investigator, Master Agreement, Clinical Evaluation
of Investigational Antiepileptic drugs DHHS, 8/1/86-7/91 Principal Investigator, Multicenter, Double-Blind, Placebo Controlled,
Add-On, Crossover Study of Lamotrigine in Epileptic Outpatient with Partial
Seizures. Protocol 06, Burroughs Wellcome, 9/86-9/88 Principal Investigator, Safety and Efficacy of Conversion to Depakote
Monotherapy in Patients with Primary Generalized Seizures. Abbott Laboratories,
10/86 Principal Investigator, Comparison of Safety and Efficacy of Depakote
and Carbamazepine in the Treatment of Complex Partial Seizures. Abbott Laboratories,
6/87-12/89 Principal Investigator, A Multicenter Open Study of Lamotrigine
in Epileptic Outpatients with Partial Seizures. Protocol 09, Burroughs Wellcome,
l0/87-10/89 Principal Investigator, Evaluation of Flunarizine in the Treatment
of Partial Seizures, RFP-NIH-NINCDS-87-02, 12/87-12/90 Principal Investigator, Evaluation of the Acute and Chronic Dosing
of Terfenadine on Phenytoin Concentrations in Epileptic Patients. Merrell Dow,
1987 Principal Investigator, N-Glycosylation of Barbiturates and Related
Drugs. (Clinical monitoring for human experiments). Principal Investigator,
William H. Soine, Ph.D., 1/88-1/90 Co-Investigator, Medical College of Virginia Epilepsy Center,
A Genetic Study of Seizures in Twins. NIH. Principal Investigator, R.J. DeLorenzo,
Section PII, Linda Corey 1/89-12/93. Principal Investigator, Flunarizine in the Treatment of Partial
Seizures - An Open Label Extension 14,950/0302 - Janssen Research Foundation
1/89-6/90. Co-Investigator, Medical College of Virginia Epilepsy Research
Center, Status Epilepticus: A Clinical Study, NIH. Principal Investigator, R.
J. DeLorenzo. 1/1/89-12/31/98 Principal Investigator, A Multicenter, Placebo-Controlled, Parallel-Design
Phase III Evaluation of the Safety of Lamotrigine as Add-on Therapy in Outpatients
with Partial Seizures, Protocol 16, Burroughs Wellcome, 6/89-7/95 Principal Investigator, single Oral Dose Proportionality Study
of Lamotrigine in Health Normal Males, Burroughs Wellcome. Protocol 22, 9/89-11/89 Principal Investigator, A Single and Multiple Dose Tolerance Study
of FPL 12924AA in Medically Refractory Epileptic Patients, Fisions, 10/89-7/91
Co-Investigator, Comparative Pharmacokinetic Study in Epileptic
Patients Receiving Tegretol in the Form of Commercial and Oros Dosage Forms,
Ciba Geigy, 1/90-1/91 Principal Investigator, Valproate Study M89-385, IV Sodium Valproate
as Replacement Study for Depakote, Abbott Pharmaceuticals, 2/90-10/90 Co-Investigator, Single Oral Dose of Safety and Tolerance Study
of CGS-18416. Protocol 02, in Healthy Volunteers. Ciba Geigy, 9/90-10/90 Principal Investigator, Double-Blind, Randomized, Placebo-Controlled,
Parallel Group Study of Vigabatrin in Patients with Uncontrolled Complex Partial
Seizures, Marion Merrell Dow Pharmaceuticals Inc., 9/90-7/92 Principal Investigator, Rectal Administration of Diazepam for
Acute Repetitive Seizures (RADARS) RFP-NIH-NINDS-90-14: 5/91-3/95 Principal Investigator, An Open Long-Term Maintenance Study of
Vigabatrin in Patients with Uncontrolled Complex Partial Seizures, Marion Merrell
Dow Pharmaceuticals. 7/91 Principal Investigator, The Safety of Intravenous Valproate. Protocol
M90-540, Abbott Laboratories, 7/91 Principal Investigator, Safety and Efficacy of Three Dose Levels
of Tiagabine HCL Versus Placebo as Adjunctive Treatment for Complex Partial
Seizures, Abbott Laboratories 9/91 Principal Investigator, Felbamate Concentration Response Trial
(CRT) RFP-NIH-NINDS-91-01, 9/91-8/94 Principal Investigator, Four Week, Ascending Double-Blind, Multi-Dose,
Add-On, Pharmacokinetic and Tolerability Trial in Male Epileptic Patients. Ciba-Geigy
CGP 33101, 1/92 Principal Investigator, Master Agreement: Clinical Evaluation
of Investigational Antiepileptic Drugs DHHS 1/92-1/97 Principal Investigator, Open-Label Study of Intravenous Fosphenytoin
Status Epilepticus, Protocol 982-16, Parke-Davis, 2/92 Principal Investigator, Open-Label Extension Study of Tiagabine
HCL in the Treatment of Patients with Partial Seizures, Protocol M91-604, Abbott
Laboratories, 2/92 Principal Investigator, Open-Label, Long-Term, Safety of Vigabatrin
Administered Concomitantly with Antiepilepsy Drugs or as Monotherapy, Protocol
028, Marion Merrell Dow, 3/92-6/94 Principal Investigator, Compassionate Use of Felbamate in Patients
with Epilepsy. Protocol 242C. Carter Wallace, 3/92 Principal Investigator, Compassionate Use of Felbamate in Pediatric
Subjects with Epilepsy, Protocol 269B, Carter Wallace, 3/92 Principal Investigator, Open-Label Study of Intravenous Fosphenytoin
Status Epilepticus. Protocol 982-16, Parke-Davis, 6/92 Principal Investigator, Open Label Study of the Safety of Long-Term
Tiagabine HCL Administration in Patients with Epilepsy. Protocol M92-813, Abbott
Laboratories, 10/92 Principal Investigator, An Open-Label, Follow-On Study of Rectal
Administration of Diazepam for Acute Repetitive Seizures, Upsher-Smith, 10/92
Principal Investigator, Open-label Follow-On, Long-Term Felbamate
Therapy in Adult Subjects with Epilepsy, Protocol 253G, Carter Wallace, 11/92
Co-Principal Investigator, Long-Term Safety and Efficacy Evaluation
of Zonisamide in the Treatment of Seizures in Medically Refractory Patients
and Efficacy Evaluation of Zonisamide Monotherapy, Protocol #810-921, Dainippon
Pharmaceutical Inc., 12/92 Co-Principal Investigator, Baseline Controlled Safety and Efficacy
Evaluation of Zonisamide in the Treatment of Seizures in Medically Refractory
Patients, Protocol #810-920, Dainippon Pharmaceutical Inc., 12/92 Co-Principal Investigator, Open Label, Multicenter Study Assessing
the Safety and Tolerance of an Intramuscularly Administered Loading Dose of
Fosphenytoin (CI-982) in Patients Requiring a Loading Dose of Phenytoin, Protocol
#982-002, Parke-Davis, Warner Lambert, 1/93 Co-Principal Investigator, Multi-Dose Evaluation of Pharmacokinetics
and Safety of a Multi-Unit Dose of Carbamazepine. PI 101.103, Pharmavene, Inc.,
4/93 Principal Investigator, A Protocol to Provide Lamictal for the
Treatment of Serious Life Threatening Epilepsy, Protocol 26, Burroughs Wellcome,
6/93 Principal Investigator, A Double-Blind Trial of Topiramate in
Subjects with Lennox-Gastaut Syndrome, Protocol YL, Ortho-McNeil, 6/93- Principal Investigator, A Multicenter, Randomized, Double-Blind,
Comparative Study of Gabapentin (CI-945) Administered as an Initial Dosage of
900 MG/Day Versus A Dosage Titrated to 900 MG/Day Over Three Days. Protocol
945-090, Parke-Davis, 1/94-6/95 Co-Investigator, Medical College of Virginia Epilepsy Research
Center, Genetic Epidemiology of Seizures: A Twin Study of Status Epilepticus.
NIH, Principal Investigator RJ DeLorenzo, LA Corey, MD. Section PI, 7/94-6/99 Principal Investigator, Safety and Efficacy of a Single, Rectal
Administration of Diazepam for Acute Repetitive Seizures. AN094-003, Athena,
3/94 Principal Investigator, An Open Label, Follow-On Study of the
Safety and Efficacy of Intermittent Rectal Administration of Diazepam for Acute
Repetitive Seizures. AN094-004, Athena, 3/94 Principal Investigator, Clinical Experience and Use of Sabril
in Patients with Partial Seizures. Protocol VGPR0098, Marion Merrill Dow, 3/94-3/00. Principal Investigator, A Multicenter, Double-Blind, Active-Control
Evaluation of the Efficacy and Safety of Lamotrigine Monotherapy in Patients
with Partial Seizures. Protocol 30, Burroughs Wellcome, 3/94-3/96 Principal Investigator, A Multicenter, Double-Blind, Placebo-Controlled,
Parallel-Design Evaluation of Lamictal for Add-On Treatment of Partial Seizures
in Pediatric Patients, Protocol 40, Burroughs Wellcome, 4/94 Principal Investigator, Gabapentin Pediatric Monotherapy Trial:
A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study in Pediatric
Patients with Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS).
Protocol 945-094, Parke Davis, 4/94-3/97 Principal Investigator, An Extended Open-Label, Gabapentin (CI-945)
Pediatric Monotherapy Trial Following a Double-Blind Trial. Protocol 945-095,
Parke Davis, 4/94-3/97 Co-Investigator, Medical College of Virginia Epilepsy Research
Center, Genetic Epidemiology of Seizures, NIH, Principal Investigator, LA Corey,
Ph.D., 5/94-3/98 Co-Investigator, Developmental Outcomes in Adolescents with Epilepsy.
Epilepsy Foundation of America, Principal Investigator K. Sawin, Ph.D., 7/94-6/96 Principal Investigator, A Double-Blind Parallel Group Comparison
of Gabapentin Versus Placebo as Add-On Therapy for Epilepsy in Children. Protocol
186, Parke Davis, 8/94- Principal Investigator, An Open-Label Extension Study of Gabapentin
in Children with Epilepsy who have Participated in the Double-Blind Study 945-186,
Protocol 187, Parke Davis, 8/94- Sub-Investigator, A Multi-Dose Evaluation of Safety of Carbatrol
in Subjects with Seizure Disorders. Protocol 101.106, Pharmavene, 8/94- Principal Investigator, Lamotrigine as Add-On Therapy in patients
with a Clinical Diagnosis of a Lennox-Gastaut Syndrome (Severe Generalized Epilepsy
of Childhood Onset). A Multicenter, Double-Blind, Placebo-Controlled, Parallel
Group Study. Protocol 123, Burroughs Wellcome, 9/94-11/95 Principal Investigator, Efficacy and Safety Evaluation of Oral
Adjunctive Vigabatrin (Sabril®) Therapy Compared to Placebo in Children
with Uncontrolled Complex Partial Seizures: A Dose Response Study. Protocol
118, Marion Merrill Dow, 1/95-12/96 Consultant, Prognosis of Children with a First Unprovoked Seizure,
NIH, PI Shlomo Shinnar, 1995-1998 Principal Investigator, An Open-Label Study of the Safety of Rectal
Administration of Diastat® (Diazepam) in Patients with Epilepsy. Study AN094-305,
Athena Neurosciences, 2/95-8/95 Principal Investigator, Safety and Efficacy of Tiagabine HCl as
Adjunctive Treatment, Protocol M92-825. Abbott Laboratories, 2/95-4/97 Principal Investigator, A Double-Blind, Randomized, parallel-Group,
Single-Dose, Multi-Center, Safety, Tolerance, and Pharmacokinetic Study of Intravenous
fosphenytoin (Cerebyx) Versus Intravenous Dilantin in Patients Requiring a Loading
Dose of Phenytoin, Protocol 982-26, Parke Davis, 3/95 Principal Investigator, An Open-Label Study of Lamictal in Patients
who Previously Participated in a Lamictal Pediatric Trial, Protocol 41, Burroughs
Wellcome, 4/95- Principal Investigator, A Long-term, Multi-dose Evaluation of
Safety of Carbatrol in Subjects with Seizure Disorders. Protocol PI 101.111,
Pharmavene, 6/95- Principal Investigator, An Open-Label, Follow-up, Long-term Maintenance
Study of Vigabatrin as Adjunctive Therapy in Children with Uncontrolled Complex
Partial Seizures. Protocol 071754PR0201, Marion Merrill Dow, 7/95- Principal Investigator, Remacemide Inpatient Seizure Evaluation
Trial CR 2268 (ACV-201), Astra-Merck/NIH, 7/95-12/96 Principal Investigator, A Long-term Follow-on Study of Remacemide
Hydrochloride for Safety and Tolerability in Patients with Medically Refractory
Epilepsy CR 427(ACV-201C), Astra-Merck/NIH, 7/95-12/96 Sub-Investigator, A Multicenter Continuation of Lamictal Monotherapy
Studies. Protocol 29, Burroughs Wellcome 7/95-2/97 Principal Investigator, Follow-up Safety Evaluations in Selected
Patients Treated with Vigabatrin. Protocol 071754PRO253, Hoescht Marion Roussell,
1/96-3/96 Principal Investigator, An Open-Label Study to Evaluate the Safety,
Tolerability, and Efficacy of Ganaxolone as an Add-on Therapy in Patients with
Infantile Spasms. Protocol 1042-0101, CoCensys, 1/96-5/97 Principal Investigator, An Open-Label, Safety, Tolerance, and
Pharmacokinetic Study of Intravenous and Intramuscular Fosphenytoin (Cerebyx)
in Children Less Than 5 Years of Age Protocol 982-028. Parke Davis, 3/96-98 Principal Investigator, Changes in Clearance of Antiepileptic
Drugs During Puberty. NIH-NINDS-96-05, 12/1/96-8/1/98. Principal Investigator, Telephone Validation of the Quality of
Life in Epilepsy (Qolie-89) Inventory, Project A2-1134, Med-Tap, 3/97-6/97 Principal Investigator, An Open-Label Extension Study of Tiagabine
HCl in the Treatment of Pediatric Patients with Partial Seizures, M96-460, Abbott
Laboratories, 3/97-99 Principal Investigator, Study No. NIH-NJNDS-96-11, Losigamone
As Monotherapy In The Treatment Of Complex Partial Seizures, NIH, 8/97-10/99 Principal Investigator, A Multi-Center, Open-Label, Exploratory
Study of UCB L059 in Children (6-12 years old) with Partial Onset Seizures.
ucb Pharma, Inc., 9/97-9/98. Principal Investigator, An Open-Label Clinical Investigation to
Evaluate the Safety & Tolerability of Ganaxolone in the Treatment of Pediatric
Patients with Epilepsy. Protocol 1042-0113.01, CoCensys, Inc., 9/97-98 Principal Investigator, An open-label study of Topamax (Topiramate)
in subjects with infantile spasms, Protocol #TOPMAT-EPIS-003, 3/98-5/00. Principal Investigator, An inpatient, double-blind, placebo-controlled,
parallel group study of Remacemide hydrochloride as monotherapy in subjects
with partial-onset seizures, 5/98-12/99. Chairman, Medical Safety Board, Treatment of seizures in the elderly
population. Veteran’s Administration Cooperative study #428, 6/98 - Principal Investigator, Protocol #199, A Long-Term Open Label
Safety Study of Remacemide in Subjects with Epilepsy, 09/98-5/00. Principal Investigator, Protocol ZNS-401: Open-Label Dose Titration
Assessment of the Clinical Utility of a Slow, Low Dose Titration Schedule of
Zonegran ® in the Initiation of Therapy in Patients with Partial Seizures,
01/07/99-12/00 Principal Investigator, "Gabapentin Pediatric Add-On Trial:
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter
Study in Patients with Partial Seizures (Protocol 945-305).", 03/09/99-12/99. Principal Investigator, "Open-Label Safety Study of Gabapentin
(CI-945) as Adjunct Therapy in Children Aged 1 Month Through 4 Years With Seizures
Uncontrolled by Current Anticonvulsant Drugs (Protocol 945-301).", 03/09/99-06/01. Principal Investigator, "The Safety and Tolerance of Intravenous
Depacon at an Infusion Rate up to 3.0 mg/kg/minute in Subjects with Epilepsy
(Protocol M98-938), 06/24/99-12/99. Sub-investigator, Multi-center, Randomized, Double-blind, Placebo-Controlled,
Parallel-Group, Monotherapy Study of Rufinamide in Inpatients with Refractory
Partial Seizures Who Have completed an Evaluation for Epilepsy Surgery. CRUF331-
0038, 7/99- Co-Investigator, Multicenter, Randomized, Double-blind, Placebo-controlled,
Parallel-Group, Monotherapy Study of Rufinamide in Inpatients with Refractory
Partial Seizures Who Have Completed an Evaluation for Epilepsy Surgery., Novartis,
CRUF331-0038, 2/99. Principal Investigator, "Evaluation of the Efficacy and Tolerability
of Levetiracetam Add-On Treatment in Refractory Pediatric Patients with Partial
Onset Seizures: A 28-week Double Blind, Placebo-Controlled Multicenter Trial".
UCB Pharma Inc., Protocol No. - RPCE98B2502. 08/99. Principal Investigator, "A Multicenter, Open-Label, Safety
and Efficacy Study of Zonegran In Patients with Progressive Myoclonic Epilepsy
ZNS-502. 3/00-05/01. Principal Investigator, Protocol LAM200006: A Double-Blind, Placebo-Controlled,
Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of LAMICTAL
in Pediatric Age subject (1-24 months), 8/16/00. Principal Investigator, Protocol LAM20007: An Open-Label, Uncontrolled,
Long-Term Study to Assess the Safety of Lamictal in Pediatric Subjects Who Have
Previously Taken Part in Study LAM20006, 8/21/00. Principal Investigator, A Multicenter, Open Label, Long-Term,
Follow-up Study of the Safety and Efficacy of Levitracetam (UCB L059) in Children
with Epilepsy. Study 157. 08/24/00. Sub-Investigator, Protocol ZNS-501. " A Multicenter, Open-Label,
Safety Study to Evaluate the Use of 25 mg and 50 mg Zonegran (zonisamide) in
the Initiation of Therapy in Patients with Epilepsy.", 10/00. Sub-Investigator, "Neurodevelopmental Effects of Antiepileptic
Drugs (NEAD), 06/01/01-05/31/05. Sub-Investigator, "Open Label, Long-Term Safety Study of
Zonisamide (Zonegran) Administered To Children With Epilepsy". AN46046-354.
02/01. Sub-Investigator, Protocol 982-040-004: "An Open Label Study
of the Effects of Intravenous Fosphenytoin (Cerebyx) on Plasma Formate, Phosphate,
and Calcium Concentration in Neonatal Pediatric Patients", 05/01. Principal Investigator - MCV, Shinnar S, "Consequences of
Prolonged Febrile Seizures in Childhood", NIH, Pending 2001. Director, IEC, Data Management, "Pilot Trial of Thalamic
Stimulation for Epilepsy". NINDS IR01 NS 39344-01. 04/01/01. Consultant, "Early Randomized Surgical Epilepsy Trial (ERSET)",
Pharmacotherapy Review Committee, 10/2000. Dr. Pellock is medical monitor for the following projects performed
with William H. Barr, Pharm. D., Ph.D., Chairman, Department of Pharmacy and
Pharmaceutics, Principal Investigator, as part of the Biopharmaceutical Research
Center: Diazepam Bioavailability Study, 5 mg Single Dose in Subjects Pre-dosed
with Ranitidine, Parallel Design. September 1985-September 1986 Diazepam Bioavailability Study, 5 mg Single Dose in Subjects Pre-dosed
with Ranitidine. October 1985-October 1986 Diazepam Bioavailability Study, 5 mg Single Dose in Subjects Pre-dosed
with Ranitidine - Extension of 85-C8"October 1985-October 1986 Bioavailability of Diazepam (Valium®) 10 mg) Tablets and Generic
Diazepam (Myland 10 mg) Tablets in Normal Volunteers. January 1986-January 1987 Bioavailability of Controlled Release Drug Products Containing
Pseudoephedrine and Chlorpheniramine. February 1986-February 1987 Bioavailability of Controlled Release Drug Products Containing
Pseudoephedrine. February 1986-February 1987 Bioavailability of Controlled Release Drug Products Containing
Pseudoephedrine and Triprolidine. February 1986-February 1987 Diazepam Bioavailability Study, 5 mg Single Dose in Subjects Pre-dosed
with Ranitidine. May 1986-May 1987 Two-way, randomized crossover study in 18 healthy male subjects
using a controlled-release product containing PPA 150 mg/CPM 24 mg/DEX 120 mg
as compared to a standard dose of PPA (given as Propagest Tablets), the antihistamine
(given as Chlortrimeton Tablets) and the expectorant (given as Benylin Syrup),
every 8 hours. May 1986-November 1987 Bioequivalence of Clofibrate 500 mg Capsules (Zenith) Compared
to Clofibrate 500 mg Capsules (Ayerst) in a 2-Way Single Dose Study. September
1986-September 1987 Single Dose Study of Ibuprofen-CR 600 mg (controlled release)
tablet versus Ibuprofen-IR(Motrin immediate release 2x300 mg)600 mg Under Fed
and Fasting Conditions. August 1987-September 1988 Evaluation of Visken Oral Once-A-Day Dosage Forms. A Pilot Study
to determine the effect of food on the Bioavailability of Visken MR2 in Healthy
Male Volunteers. October 1987-November 1988 Multicenter Placebo Controlled Parallel Design Phase III Evaluation
of the Safety of Lamotrigine as Add-On Therapy in Patients with Partial Seizures.
June 1989-December 1990 Single Oral Dose Safety and Tolerance Study of CGS-18416, Protocol
02, in Healthy Male Volunteers. September 1990-October 1990 Member of Editorial Board, Living with Epilepsy, Patient Handbook
published through Parke-Davis and The KSF Group, 1992 Editorial Board - Journal of Child Neurology, 1997- Editorial Board - Journal of Pediatric Pharmacology and Therapeutics,
2000- Editorial Board- Journal of Epileptic Disorders, 2000- Editorial Board, Clinical Decision-Making in the Management of
Epilepsy, 2000- Editorial Board, Pediatric Neurology, 2000- Guest Reviewer - Neurology, 1979- Editor for Neurology, Practice of Pediatrics, 1980-1988 Editor, Neurologic Emergencies in Infancy and Childhood, Philadelphia,
Harper and Row/Lippincott, 1984 Guest Reviewer - Epilepsia, 1986- Editor, Child Neurology Society Newsletter, 1986-1988 Guest Editor, Pediatric Clinics North America, Seizure Disorders,
1989 Guest Reviewer - Drug Safety, 1991- Editor for Neurology, Drug Evaluations, American Medical Association,
1991-1994 Guest Reviewer - American Journal on Mental Retardation, 1992 Guest Reviewer - Pediatrics, 1993- Editor, Pediatric Epilepsy, Diagnosis and Therapy, New York, Demos,
1993 Editor, Neurologic Emergencies in Infancy and Childhood, 2nd Edition,
Stoneham, MA, Butterworth Heinemann, 1993 Editor, Promise and Progress in the Treatment of Epilepsy. Epilepsia,
Vol. 34, Supplement 5, 1993 Guest Reviewer - Epilepsy Research, 1994- Guest Reviewer - Drugs, 1994- Guest Reviewer - Journal of Pediatrics, 1994- Guest Reviewer - Mayo Clinic Proceedings, 1995- Editor, ADHD Alert, Division of Child Neurology, Virginia Commonwealth
University, 1995- Editor and Chairman, Epilepsy Interface, Center for Bio-Medical
Communications, Inc., 1995-1996 Guest Editor, Pharmacy and Therapeutics, May, 1996 Guest Editor, Seminars in Pediatric Neurology, New Antiepileptic
Drugs in Childhood Epilepsy, 1997;4(1) Guest Editor, Lamotrigine, Journal of Child Neurology, Vol. 12,
Supplement 1, 1997 Editor, Perspectives in Pediatric Neurology, Virginia Commonwealth
University, 1999- Guest Reviewer: CNS Drugs, 2000- Editor, Pediatric Epilepsy: Diagnosis and Therapy, Second edition,
New York: Demos Publication, 2001 Editor, Broadening the spectrum of clinical uses of antiepileptic
drugs, London: Royal Society of Medicine Press Limited, 2000 Speaker for "Recent Developments in the Treatment of Epilepsy",
Speakers Bureau funded by Abbott Pharmaceutical Laboratories, 1980- Ciba Geigy/Novartis Symposia Lecture Series, Epilepsy and Child
Neurology, Ciba-Geigy Pharmaceutical Laboratories, 1981- Planning Committee, Annual Conference, Rehabilitation of the Head
Injured Adult and Child, Williamsburg, VA, 1984-1989 National Institute of Health, Ad Hoc site visitor for General
CRC Section University of Michigan, Ann Arbor, 11/95 Examiner, American Board of Psychiatry and Neurology, (Child Neurology)
1985- Visiting Faculty, Childhood Epilepsy and Pharmacology, Epilepsy
MiniFellowship, Bowman-Gray School of Medicine, Wake Forest University, 1987-,
Board of Directors, 1996- Director and Lecturer, Epilepsy Forum 1987, Scottsdale, Arizona
September and November 1987 Director and Lecturer, Epilepsy Forum 1988, Naples, Florida February
1988; Scottsdale, Arizona March and May 1988; Palm Desert, California June 1988,
Naples, Florida October 1988 Lecturer, Epilepsy, Merritt Putnam National Speakers Bureau, Parke-Davis
Pharmaceutical Lecture Series. 1988- Director and Lecturer, Neurology for the Practitioner, Medical
College of Virginia of Virginia Commonwealth University, Continuing Medical
Education, Williamsburg, VA, April 1989 Lecturer, Status Epilepticus Series, Wyeth Laboratories. 1988
Ad hoc Reviewer, National Institutes of Health Review Panel for
Neonatal Seizures - Evaluation for Center Grants, National Institutes of Health,
Bethesda, Maryland, July 1-3, 1990. Lecturer, Epilepsy Update, A Postgraduate Course on Clinical Epilepsy,
Sponsored by Parke-Davis Pharmaceuticals and the Epilepsy Research Foundation
of Florida, 1991- Lecturer, Neurology Educator Access Program, New Insights in Contemporary
Epileptology. Sponsored by Carter Wallace Laboratories, 1993 Lecturer, New Antiepileptic Drugs, Pediatric Epilepsy and Status
Epilepticus, Parke-Davis Speakers Bureau, 1993- Course Director and Lecturer, Hans Berger Annual Symposium. Medical
College of Virginia of Virginia Commonwealth University, 1994- National Institutes of Health, Pediatric Epilepsy Consensus Panel,
1994 Advisor, Epilepsy Branch, NINDS, 1995 Ad Hoc Reviewer, National Institute of Health, 1995-1996 Organizing Committee and Lecturer, Antiepileptic Drug Trials III.
University of Pennsylvania. Charleston, South Carolina, March 1996 ID&A/Ortho McNeil Speakers Bureau, 1996- Committee Director, Pediatric Grand Rounds: Epilepsy, Epilepsy
Foundation of Florida/Parke Davis, 1997 Program Director, Maximizing Benefits from New AEDs in the Developmentally
Disabled, NeuroTech, 1997-1998 Course Instructor, Spectrum of activity of new antiepileptic drugs:
which patients will benefit?, American Epilepsy Society CME Activity, aesnet.org,
1999. Antiepileptic Treatment Symposium (Course Co-Director), American
Epilepsy Society, 2000-2002 Rowland LP, DiMauro S, Schotland DL, Bonnilla E, Berenberg R,
Pellock JM, and Vicale CT: Lumping or Splitting: Ophthalmoplegia-Plus or Kearns-Sayre-Daroff
Syndrome? Third International Congress on Muscle Disease, Newcastle-Upon-Tyne,
September, 1974 Pellock JM, Pippenger CE, Gold AP: Depression of Antiepileptic
Drug Concentration Following Concomitant Administration of Antacids in Children.
Fifth National Meeting of the Child Neurology Society, Hamilton, Ontario, October,
1975 Pellock JM, Pippenger CE, Marlette-Brown R, and Lynch D: Plasma
Concentrations of Antiepileptic Drugs in Children. First International Congress
of Child Neurology, Toronto, Ontario, October, 1975 Pippenger CE, Pellock JM, Marlette-Brown, et al: Plasma Concentrations
on DPH, Phenobarbital and Primidone in Children. IV Panamerican Congress of
Neurology, Mexico City, October, 1975 Pellock JM, Berenberg R, DiMauro S, et al: Lumping or Splitting:
Ophthalmoplegia-Plus or Kearns-Sayre-Daroff Syndrome? 101st Annual Meeting of
American Neurological Association, San Francisco, June, 1976 Pippenger CE, Pellock JM, Gold AP: Antiepileptic Drug Concentrations
in Children on Multiple Therapy. Workshop on the Determination of Antiepileptic
Drugs in Biological Fluids. WODADIBF III, Bethel, Germany, August, 1976 Koenigsberger MR, Pellock JM, DiMauro S, Eastwood A: Juvenile
Mitochondrial Myopathy, Short Stature and Lactic Acidosis: A Clinical Ultrastructural
and Biochemical Study. Sixth National Meeting of the Child Neurology Society,
Monterey, California, October 1976 Britton DE, Pellock JM, Eiben RM: Acute Hemiplegia of Childhood,
Lactate-pyruvate Acidemia, and Mitochondrial Disorder. Seventh Annual Meeting
of the Child Neurology Society, Charlottesville, Virginia, October, 1977 Carter BL, Garnett WR, Pellock JM, et al: Interaction between
Phenytoin and Three Commonly Used Antacids. American Society of Hospital Pharmacists
Midyear Clinical Meeting, Las Vegas, Nevada, December 6, 1979 Hamilton RA, Garnett WR, Kline BJ and Pellock JM: The Effects
of Food on Valproic Acid Absorption. Midyear Clinical Meeting of the American
Society of Hospital Pharmacists, San Francisco, California, December 8, 1980 Pellock JM: Recent Developments in the Treatment of Epilepsy.
Delaware Academy of Family Physicians, Delaware, October 29, 1980 Pellock JM: Convulsive Disorders in Childhood. Arkansas Academy
of Family Physicians, Little Rock, Arkansas, August 8, 1981 Garnett WR, May CA, Small RE, Pellock JM: The Effects of Antacids
on the Bioavailability of Valproic Acid. Midyear Clinical Meeting of the American
Society of Hospital Pharmacists, New Orleans and Los Angeles, December, 1981 Phelan MC, Pellock JM, Nance WE: Discordant Expression of Fetal
Hydantoin Syndrome in a Pair of Dizygotic Twins with Different Fathers. American
Society of Human Genetics, Boston, Massachusetts, October, 1981 Pellock JM, Phelan MC, Mamunes P, Nance WE: Fetal Hydantoin Syndrome-Multifactorial
Causation. Third International Child Neurology Congress, Copenhagen, Denmark,
1982 Flannery DB, Pellock JM, Bousounis D, et al: Nonketotic Hyperglycinemia
in Retarded Adult Siblings. American Society of Human Genetics, 33rd Annual
Meeting, Detroit, Michigan, September, 1982 Pellock JM, Flannery DB, Mamunes P, Robertson LW: The Fetal Primidone
Syndrome. Twelfth Annual Meeting of the Child Neurology Society, Salt Lake City,
October, 1982 March CL, Garnett WR, Poynor WJ, Pellock JM: Effects of Exercise
on Valproic Acid Pharmacokinetics. Midyear Clinical Meeting American Society
of Hospital Pharmacists, Los Angeles, December, 1982 Pellock JM, Phelan MC, Mamunes P, Nance WE: Fetal Hydantoin Syndrome-Multifactorial
Causation. 15th Epilepsy International Symposium and American Epilepsy Society
Meeting, Washington, D.C., September 26 to 30, 1983 Pellock JM: Fetal Antiepileptic Drug Syndromes: Presenting Signs
and Symptoms. 15th Epilepsy International Symposium and American Epilepsy Society
Meeting, Washington, D.C., September 26-30, 1983 Garnett WR, Hamilton RA, May CA, Pellock JM: Valproic Acid Pharmacokinetics
when Food and Antacids are used for Gastrointestinal Distress. 15th Epilepsy
International Symposium and American Epilepsy Society Meeting, Washington, D.C.,
September 26-30, 1983 Garnett WR, March CL, Tarasidis CG, Pellock JM: Assessment of
Total and Free Valproic Acid Levels in Serum and Plasma in Children. 13th Annual
Meeting of the Child Neurology Society, Williamsburg, VA, October, 1983 Pellock JM, Carzo G, Garnett WR: Carbamazepine in Children: Clinical
and laboratory adverse effects. 14th Annual Meeting, Child Neurology Society,
Phoenix, AZ, October, 1984 Garnett WR, Pugh CB, Pellock JM: Validation and Chronic Usefulness
of a Single Dose Prediction Model to Forecast the Total and Free Steady State
Concentrations of Valproic Acid in Epileptic Patients. Annual Meeting American
Epilepsy Society, San Francisco, California, November, 1984 Tarasidis CG, Garnett WR, Kline BJ, Pellock JM: The Effect of
Tube Type Storage Time and Temperature on the Total and Free Concentration of
Valproic Acid. Annual Meeting American Epilepsy Society, San Francisco, November,
1984 Pellock JM, Carzo CG, Garnett WR: Carbamazepine in Children: Efficacy
and Adverse Effects. Annual Meeting American Epilepsy Society, November, 1984 Pugh CG, Garnett WR, Poynor WT, Pellock JM: Prediction of Steady
State Valproic Acid Serum Concentrations in Seizure Patients using the Single
Dose Prediction Model. 19th Annual American Society of Hospital Pharmacists
Midyear Clinical Meeting, Dallas, Texas, December, 1984 Maas B, Garnett WR, Comstock TJ, Pellock JM: A Comparison of the
Relative Bioavailability and Pharmacokinetics of Carbamazepine Tablet and Chewable
Tablet Formulations. 15th Annual Meeting, Child Neurology Society, Memphis,
TN, October, 1985 Fitzsimmons WE, Garnett WR, Comstock TJ, Pellock JM: Single Dose
Comparison of the Relative Bioavailability of Phenytoin Suspension and Extended
Capsules. American Epilepsy Society Annual Meeting, New York, December, 1985 Hubbell JP, Garnett WR, Pellock JM, Chern WH, Wargin WA, Lai A,
Cloutier G: Pharmacokinetics of Lamotrigine (BW430C) in Epileptic Patients.
American Epilepsy Society, Annual Meeting, New York, 1985 Pellock JM, Garnett WR, Fitzgerald BE, Valakas A, Lai A, Cloutier
G: Acute Dose Tolerance of Lamotrigine (BW430C) in Epileptic Patients. American
Epilepsy Society, Annual Meeting, New York, 1985 Pellock JM: Carbamazepine: Adverse Effects in Children and Adults.
Carbamazepine's Place in Antiepileptic Drug Therapy. Ciba-Geigy. St. Thomas,
USVI, April 13 and May 20, 1986 Pellock JM: Role of Antiepileptic Medications on Cognitive Functions.
International Head Injury Association, Williamsburg, VA, June, 1986 Maas B, Garnett WR, Pellock JM: Adverse Effects Associated with
Long-term Use of Valproic Acid in Children. Annual Meeting, Child Neurology
Society, Boston, October, 1986 Pellock JM: Seizures, Cognitive Function, and Anticonvulsants.
Council for Exceptional Children, National Early Childhood Conference on Children
with Special Needs, Louisville, Kentucky, October 19-21, 1986 (Invited) Allport CD, Erskine S, Pellock JM: Clinical Consultation Model
for Early Intervention Programs. Council for Exceptional Children, National
Early Childhood Conference on Children with Special Needs, Louisville, Kentucky,
October 19-21, 1986 Horowitz IW, Pellock JM, et al: When to Access Related Services.
Critical Issues for Critical Times, Virginia Association for Children with Learning
Disabilities, Lynchburg, VA, November 14, 1986 Lai A, Wargin WA, Garnett WR, Pellock JM et al: Pharmacokinetics
of Lamotrigine in Epileptic Patients Following Multiple Oral Dosing, American
Epilepsy Society Annual Meeting, Seattle, WA, November, 1986 Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Pellock JM
et al: Effect of Two Administration Schedule of an Enteral Nutrient Formula
(ENF) on Phenytoin, Seattle, WA, November, 1986 Pellock JM, Garnett WR, Ramsey RE et al: Tolerance of Lamotrigine
in Epileptic Patients, American Epilepsy Society Annual Meeting, Seattle WA,
November, 1986 Pellock JM: The Role of Anti-seizure Medication on Cognitive Function.
Annual Professional Conference, Connecticut Traumatic Brain Injury Association,
Cromwell, Conn, December 1, 1986 (Invited) Garnett WR, Carson SP, Pellock JM et al: Comparison of Carbamazepine
and 10,11 - Diepoxide CBZ Plasma Levels in Children Following chronic Dosing
with Tegretol Suspension and Tegretol Tablets. America Academy of Neurology,
Annual Meeting, New York, April 7, 1987 Pellock JM: Carbamazepine: Adverse Effects in Children and Adults.
St. Thomas USVI, May 25, 1987 and Banff, Alberta, Canada, October 9, 1987 Pellock JM, Special Considerations for Children with Seizures.
Epilepsy Forum 1987: Scottsdale, Arizona- September 17-19, November 19-21, 1987 Pellock JM, Culbert JP, Garnett WR et al: Comparative Effects
of Carbamazepine, Phenytoin and Phenobarbital on Cognition and Behavior in Epileptic
Children. Annual Meeting. Child Neurology Society, San Diego, California, October
23, 1987 Pellock JM: Lorazepam: Is it the drug of choice for Status Epilepticus
in 1987? American Academy of Pediatrics Annual Meeting, New Orleans, Louisiana,
November 2, 1987 (Invited) Pellock JM: Valproate and the Generalized Epilepsies. American
Epilepsy Society Pre-meeting Symposium on Valproate and Epilepsy. Baltimore,
Maryland, December 5, 1987 (Invited) Pellock JM: Neurocutaneous Syndromes with Epilepsy, in Epilepsy
and Genetics. American Epilepsy Society Annual Course, Baltimore, Maryland,
December 6, 1987 (Invited) Pellock JM, Culbert JP, Garnett WR et al: Assessment of Cognitive
and Behavioral Effects of Carbamazepine, Phenytoin and Phenobarbital in School-aged
Children. American Epilepsy Society Annual Meeting, Baltimore, Maryland, December
7, 1987 Coniglio AA, Garnett WR, Pellock JM et al: Effect of Acute and
Chronic Terfenadine on Free and Total Serum Phenytoin Concentrations in Epileptic
Patients. American Epilepsy Society, Annual Meeting, Baltimore, Maryland, December
8, 1987 Pugh CB, Garnett WR, Pellock JM: Long Term Usefulness of a Single
Dose Prediction Model in Seizure Patients Receiving Valproic Acid Therapy. 22nd
Mid-Year Clinical Meeting, American Society of Hospital Pharmacists, Atlanta,
GA, December 8, 1987 Pellock JM: Special Considerations for Children with Seizures.
Epilepsy Forum 1988: Naples, Florida, February 2-4, October 27-29; Scottsdale,
Arizona, March 10-12, May 5-7; Palm Desert, California, June 16-18, 1988 Pellock JM: Carbamazepine: Adverse Effects in Children and Adults.
Ft. Lauderdale, Florida, March 20-22; Hot Springs, Virginia, June 2-4; Banff,
Alberta, Canada, September 29-October 1, 1988 Pellock JM, Culbert JP, Garnett WR, et al: Antiepileptic Drug
Cognitive and Behavioral Effects in Children. Cleveland Clinic International
Epilepsy Symposium on Pediatric Epileptology, Cleveland, Ohio, May 19, 1988 Garnett WR, Pellock JM: Comparison of Carbamazepine Tablets, Chewable
Tablets, and Suspension. Cleveland Clinic International Epilepsy Symposium on
Pediatric Epileptology, Cleveland, Ohio, May 20, 1988 Pellock JM, et al: Significant differences of AEDs cognitive and
behavioral effects in children. Child Neurology Society, Halifax, Nova Scotia,
September 17,1988 Driscoll SM, Jack RL, Teasley JE, Towne AR, Pellock JM, DeLorenzo
RJ: Mortality in childhood status epilepticus. Child Neurology Society, Halifax,
Nova Scotia, September 15-18, 1988 Pellock JM for the Collaborative Study Group, Medical College
of Virginia: Use of carbamazepine and phenytoin in the treatment of epilepsy
in children under six years of age. Child Neurology Society, Halifax, Nova Scotia,
September 17,1988, American Epilepsy Society, San Francisco, California, October
17, 1988 Ramsay BE, Wilder BJ,...Pellock JM, et al: Conversion of polytherapy
to valproate monotherapy in patients with tonic-clonic seizures. American Epilepsy
Society, San Francisco, California, October 17, 1988 Pellock JM: Special Epilepsy Syndromes. Epilepsy Forum 1989: Naples,
FL, October 27-30, 1988 Pellock JM, Culbert JM, Garnett WR, et al: Significant Differences
of Antiepileptic Drugs Cognitive and Behavioral Effects in Children. American
Academy of Neurology, Chicago, April 15, 1988 Ramsay RE, Wilder BJ,...Pellock JM, et al: Conversion of polytherapy
to valproate monotherapy in patients with tonic-clonic seizures. American Epilepsy
Society, San Francisco, October 17, 1988 Pellock JM: Special Epilepsy Syndromes. Epilepsy Forum 1989: Scottsdale,
AZ, February 9-12, 1989; Monterey, CA, March 9-12, 1989; Toronto, Canada, May
11-14, 1989; Montreal, Canada, June 8-11, 1989 Pellock JM, Culbert JP, Garnett WR, et al: Significant differences
of AED's cognitive and behavioral effects in children. American Academy of Neurology,
Chicago, April 15, 1989. Pellock JM: Carbamazepine: Adverse Effects in Children and Adults.
Tucson, AZ, June 18-20, 1989; Banff, Alberta, Canada, November 16-19, 1989 Pellock JM: Treatment of the Primary Epilepsies. Epilepsy Forum
1989: San Francisco, CA, August 17-20, 1989 Pellock JM: Juvenile myoclonic epilepsy: An overview. Juvenile
myoclonic epilepsy symposium at Child Neurology Society meeting, San Antonio,
Texas, October 12, 1989. Pellock JM: Chronic Epilepsy in Children. World Congress of Epilepsy,
New Delhi, India, October 17, 1989. Pellock JM: Epilepsy in Childhood. American Epilepsy Society,
Boston, MA, December 3, 1989. Pellock JM: Conversion of Polytherapy to Valproate Monotherapy
in Patients with Tonic-Clonic Seizures. American Epilepsy Society, Boston, MA,
December 2, 1989. Pellock JM: Valproate and the Redefined Profile of Hepatotoxicity
Risk. Epilepsy Forum Review, Atlanta, Georgia, January 13, 1990. Pellock JM: Treatment of the Primary Epilepsies. Epilepsy Forum
1990: Scottsdale, Arizona, February 22-25, 1990, Naples, Florida, March 29 -
April 1, 1990. Pellock JM: Status Epilepticus. Carbamazepine's Place in Antiepileptic
Drug Therapy. Fort Lauderdale, Florida, April 18-22, 1990; Phoenix, Arizona,
October 10-11, 1990. Driscoll SM, Pellock JM, Towne A, et al: Recurrent Status Epilepticus
in Children. American Academy of Neurology, Miami, Florida, May 3, 1990. Pellock JM, Corey LA, Nance, WE, et al: Febrile Seizures and Epilepsy
in Virginian and Norwegian Twins and their Offspring. American Academy of Neurology,
Miami, Florida, May 4, 1990. Corey LA, Berg K, Pellock JM, et al: Seizures in Virginian and
Norwegian Twin Kindreds. International Conference on Genetics and Epilepsy.
Minneapolis, Minnesota, July 19-22, 1990. Pellock JM: Idiosyncratic Toxicity of Antiepileptic Drugs. The
Medical Management of Epilepsy Syndromes: Focus on Primary AEDs, Boston, Massachusetts,
August 17-19, 1990. Pellock JM: Rational Use of Valproate in Adults and Children.
Valproate-Associated Hepatotoxicity Workshop, San Diego, California, August
12-14, 1990 Pellock JM: Hepatic Adverse Effects of Antiepileptic Drugs, and
Hematologic Adverse Effects of Antiepileptic Drugs. University Hospitals of
Cleveland, Ohio September 22, 1990. Pellock JM, Corey LA, Bert K, Nance WE, Sollas MH, DeLorenzo RJ:
Seizures in the Offspring of Virginia and Norwegian Twins. 19th Annual Meeting
of the Child Neurology Society, Atlanta, Georgia, October 18-20, 1990. Risner, ME and the Lamictal Study Group. (Pellock JM, et al) A
Multicenter, Double-Blind, Placebo (PBO) - Controlled, Add-On, Crossover Study
of Lamotrigine (Lamictal®, LTG) in Epileptic Outpatients with Partial Seizures,
American Epilepsy Society, San Diego, CA, November 10-15, 1990. Ramsay RE, Uthman IL, Pellock JM, Wilder BJ, Garnett W, Grosz
R: The Cardiovascular Safety and Tolerance of Intravenous (IV) Sodium Valproate
as Replacement Therapy for Oral Divalproex Na: A Double-Blind, Placebo Controlled
Study, American Epilepsy Society, San Diego, CA November 12-15, 1990. Pellock JM: Pitfalls in Epilepsy Therapy. Advanced Concepts in
Patient Management. Epilepsy Forum 1991. (Abbott Laboratories) Tucson AZ 2/15/91,
Naples FL 3/22/91, Dana Point CA 4/12/91, Atlanta, Ga 5/18/91, Chicago, IL 6/14/91,
Boston, Ma 8/2/91, Indianapolis, In 8/23/91, Washington, D.C. 9/6/91, Philadelphia,
Pa 11/1/91, Houston, TX 11/15/91. Pellock JM: Status Epilepticus. Epilepsy: Current Therapy and
New Considerations. Ciba Geigy. Tucson, AZ 2/21/91, Hilton Head, SC 5/24/91. Pellock JM: Epilepsy Update. Side Effects and Toxicity, Treatment
of Infants and Children. Park-Davis. Palm Beach, FL 3/14/91. Laguna Niguel,
CA 6/7/91. Dallas, TX 10/13/91. Pellock JM: Diagnosis and Treatment of Seizures, Approach to the
Refractory Epileptic Child, Advances in Antiepileptic Drug Therapy, Neurological
Trauma, Acute Neurological Disorders, and Childhood Stroke. Current Concepts
in Child Neurology, Children's Hospital San Diego, Ca, June 21-23, 1991. Pellock JM: Pediatric Epilepsy Syndromes. Epilepsy Case Studies:
Management Controversies. (Annual course) 43rd Annual Academy of Neurology Meeting,
Boston, MA 4/21/91. Pellock JM: Neuro-rehabilitation of Chronic Epilepsy. Neuro-rehabilitation
in Child Neurology Conference, 20th Annual Child Neurology Society Meeting,
Portland, Oregon, October, 1991. Pellock JM: Lamictal Efficacy and Safety: U.S. Experience. 19th
International Epilepsy Congress, Rio de Janeiro, Brazil, October 14-19, 1991. Pellock JM: Therapy and Prognosis of Status Epilepticus. 19 International
Epilepsy Congress, Rio de Janeiro, Brazil, October 18, 1991. Thakker KM, Mangat S, Faleck H, Cook T, Garnett W, Pellock J,
Farwell J, and Levy R: Steady-State Bioavailability and Fluctuations of Carbamazepine
Following Crossover Administration of q.i.d. Conventional Tegretol Tablets and
b.i.d. Tegretol OROS Tablets. American Epilepsy Society Meeting, Philadelphia,
Pa, December 6-11, 1991. Yau MK, Garnett WR, Wargin WA and Pellock JM: A Single Dose, Dose
Proportionality, and Bioequivalence Study of Lamotrigine in Normal Volunteers.
American Epilepsy Society Meeting, Philadelphia, Pa, December 6-11, 1991. Pellock JM, Hunt PA: A Decade of Modern Epilepsy Therapy in Institutionalized
Mentally Retarded Patients. American Epilepsy Society Meeting, Philadelphia,
Pa, December 6-11, 1991. Gendrom CN, Garnett WR, Culbert J, and Pellock J: The Association
Between Valproate Serum Concentration and Cognitive Function. American Epilepsy
Society Meeting, Philadelphia, Pa, December 6-11, 1991. Towne AR, Driscoll SM, Garnett WR, Castello P, Pellock JM, and
DeLorenzo, RJ: Childhood Fever and Status Epilepticus. American Epilepsy Society
Meeting, Philadelphia, Pa, December 6-11, 1991. Pellock JM: Special Considerations in Pediatric Epilepsy. Lecture
Series 1992. sponsored by Abbott Laboratories - Discovery International: The
Role of the Primary Care Physician in the Management of Epilepsy, and Practical
Clinical Guidelines for the Management of Epilepsy. Snowbird Utah February 16-19,
Scottsdale, Arizona March 5-7, New York, NY April 3, San Francisco, CA May 14-15,
1992. Pellock JM: Status Epilepticus. "Epilepsy: Current Therapy and
New Considerations" 1992 symposia sponsored by Ciba-Geigy Pharmaceuticals. Key
West, Florida February 28-29. Pellock JM: Adverse Effects of Antiepileptic Drugs. "Progress
in Epilepsy: New Concepts in Diagnosis and Management. 1992 Parke-Davis Epilepsy
Speakers Bureau Baltimore, MD, March 27. Schever RD, Cramer JA, Leppik IE, Pellock JM, Hochholzer JM, Spencer
M, O'Hara K, Muir KT: Remacemide Elimination After Initial and Chronic Dosing.
Annual American Society for Clinical Pharmacology and Therapeutics Symposium,
Orlando, FL, March, 1992. Pellock JM, Collaborative Study Group: Use of Carbamazepine and
Phenytoin in the Treatment of Epilepsy in Children under Six Years of Age. Milestones
in Epilepsy Exhibit at the 43rd Annual American Academy of Neurology Symposium,
San Diego, CA, May, 1992. Snead O, Shields WD, Hauser WA, Pellock JM: Epilepsy Case Studies:
Treatment Controversies. 43rd Annual American Academy of Neurology Meeting,
Course, San Diego, CA, May, 1992. Boggs JG, Pellock JM, Towne AR, Driscoll S, DeLorenzo RJ: A Comparison
of Recurrent Status Epilepticus in Children and Adults. 43rd Annual American
Academy of Neurology Meeting, San Diego, CA May, 1992. Pellock JM, Corey LA, Prescott C, Hewitt J, Eaves LJ, DeLorenzo
RJ: Seizure Disorders Among Twins and Their Offspring Ascertained through the
American Assoc. of Retired Persons. 43rd Annual American Academy of Neurology
Symposium, San Diego, CA, May, 1992. Salbert BA, Pellock JM, Wolf B: Characterization of Seizures Associated
with Biotinidase Deficiency. 21st Annual Child Neurology Society Symposium,
New Orleans, LA, October, 1992. Messenheimer JA, Ramsay RE, Leroy R, Zielinki JJ, Willmore LJ,
Pellock JM, Mattson R, Rudd, GD, Kearnery PA: Multicenter, Long-Term Study of
Lamotrigine (Lamictal) in Outpatients with Partial Seizures. American Epilepsy
Society Symposium, Seattle, Washington, December, 1992. Pledger GW, Sackellares JC, Treiman DM, Pellock JM, Wright FS,
Mikati M, Kupferberg H, Tsay JY, Drake ME, Olson LD: Flunarizine for Treatment
of Partial Seizures: Results of a Concentration-Controlled Clinical Trial. American
Epilepsy Society Symposium, Seattle, Washington, December, 1992. French F, Pellock JM, Ferrendelli J, et al.: Results of a Multicenter,
Placebo-Controlled, Parallel Study of Vigabatrin (VGB, Sabril® in Patients
with Focal Epilepsy Whose Seizures Are Difficult to Control. American Academy
of Neurology Meeting, New York, New York, April, 1993. DeLorenzo RJ, Towne AR, Pellock JM, et al.: A Prospective, Population-Based
Epidemiological Study of Status Epilepticus in Richmond, Virginia. American
Academy of Neurology Meeting, New York, New York, April, 1993. Pellock JM: Treatment of Epilepsy: Focus on New Antiepileptic
Drugs. Emerging Strategies in Epilepsy: Implications for the Neurologists, a
symposium held at the Annual American Academy of Neurology Meeting, New York,
New York, April 24, 1993. Pellock JM: Commentary for Update 1993: Inborn Metabolic Errors
in the Patient with Epilepsy and the Role of Carnitine, a symposium held at
the Annual American Academy of Neurology Meeting, New York, New York, April
24, 1993. Pellock JM: Phenobarbital: No Longer a First-Line Antiepilepsy
Drug. Epilepsy Case Studies: Treatment Controversies. After Dinner Seminar No.
177, American Academy of Neurology Meeting, New York, New York, April 25, 1993. Miller LL, Pellock JM, DeLorenzo RJ, Corey LA: Utilization of
Twin Kindreds in the Study of Seizure Syndromes. International Epilepsy Congress,
Oslo, Norway, July, 1993. Corey LA, Pellock JM, Miller LL, DeLorenzo RJ: Seizure Syndromes
in Virginia: A Twin Study. International Epilepsy Congress, Oslo, Norway, July,
1993. Pellock JM: A New Anticonvulsant - The US Experience of Felbamate.
A New Image in Epilepsy Symposium, November 12-14, 1993, Turnberry, Scotland,
Sponsored by Schering-Plough, Ltd. Pellock JM (Chairman): Challenges in Epilepsy: Real Patients,
Real Problems, an educational program sponsored by Abbott Laboratories at the
American Epilepsy Society Meeting, Miami, Florida, December, 1993. Pellock JM, Rao C, Earl N: Lamotrigine Efficacy and Safety Update
- U.S. Experience. American Epilepsy Society Meeting, Miami, Florida, December,
1993. Fortner C, Pellock JM, Driscoll SM, DeLorenzo RJ: Morbidity in
Children after a First Episode of Status Epilepticus. American Epilepsy Society
Meeting, Miami, Florida, December, 1993. Pellock JM: New Drugs - How to Use? Annual Southern Clinical Neurological
Society. Acapulco, Mexico, January 15-22, 1994. Pellock JM: New Antiepileptic Drugs I. Seizures and Epilepsy in
the Elderly, Issues in Diagnosis, Management, and Quality of Life. An International
Symposium. Coral Gables, Florida March 4-5, 1994 Pellock JM: Gabapentin: Safe for Children? The UCLA Pediatric
Epilepsy Program: Managing Seizures in Children: Designer Drugs or the Cutting
Edge? Palm Desert, CA, March 17-18, 1994. Pellock JM: Pediatric Considerations. Recent Progress in Epilepsy:
A Review of Basic and Clinical Advances International Symposium, International
School of Neurological Sciences, San Servolo, Venice Italy, May 12-14, 1994 Pellock JM: Seizures: Diagnosis and Treatment, American Academy
of Neurology Annual Meeting, Washington, DC, May, 1994. Pellock JM: Management of Status Epilepticus. Course No. 246 Clinical
Epilepsy. American Academy of Neurology, Washington, D.C., May, 1994. Pellock JM: Experience with New Antiepileptic Drugs in Children,
Fourth Meeting of the European Neurological Society, Barcelona, Spain, June
1994 Pellock JM: USA Experience with New AEDs, Fourth Meeting of the
European Neurological Society, Barcelona, Spain, June 1994 Pellock JM: Felbamate: Review of Clinical Experience, Fourth Meeting
of the European Neurological Society, Barcelona, Spain, June 1994 Fortner C, Pellock JM, Driscoll S, DeLorenzo R., et al Morbidity
of Status Epilepticus in Children, Child Neurology Society and International
Child Neurology Association, San Francisco CA, October, 1994. Pellock JM, Corey LA, Gaudin M, et al: Status Epilepticus in Virginia-Born
Twins and Their Families: Possible Familial Association? Child Neurology Society
and International Child Neurology Association, San Francisco CA, October, 1994. Pellock JM: Neurontin - One Year On - Clinical Experience in the
USA: A Review of Clinical Experience with new AEDs, London, England October
26, 1994. Pellock JM: Recent Advances for Treatment of Seizures in Children:
US Army Medical Department 14th Annual AMEDD Neurology Conference, Bethesda,
MD, November, 1994. Pellock JM:, Corey LA, Gaudin M, et al: Status Epilepticus: Case
Verification in an Epidemiologic Twin Study, American Epilepsy Society, New
Orleans, LA, December, 1994 Fortner C, Pellock JM, Driscoll S, DeLorenzo R., et al. Morbidity
of Status Epilepticus in Children, American Epilepsy Society, New Orleans, LA,
December, 1994 Pellock JM: Adult and Pediatric Epilepsy: Similarities and Differences
(Chairman): American Epilepsy Society, New Orleans, LA, December, 1994 Pellock JM: Therapeutic Treatment of Epilepsy in Children, American
Epilepsy Society, New Orleans, LA, December, 1994 Pellock JM: Clinical Experiences with the newly available AEDs:
Felbatol in children, Epilepsy MiniFellow Symposium VII, American Epilepsy Society,
New Orleans, LA December, 1994 Pellock JM: Seizures: Diagnosis and Treatment, (course) American
College of Physicians, Atlanta, GA March, 1995 Pellock JM: Neurontin - One Year On - Clinical Experience in the
USA: A Review of Clinical Experience with new AEDs, Edinburgh, Scotland, March,
1995. Pellock JM: A Practical Approach to the Differential Diagnosis
of ADHD: A Neurologic Perspective, Aspen, Colorado, April, 1995 Pellock JM: Combined-Modality Treatment of ADHD and Epilepsy,
Aspen, Colorado, April, 1995 Pellock JM: ADHD Today: Clinical Wisdom for the Practitioner,
Symposium Chairman, Aspen, Colorado, April, 1995. Pellock JM: Differential Diagnosis of Learning and Attentional
Problems: A Neurologists Perspective. Epilepsy, ADHD, and LD, (invited) American
Academy of Pediatrics, Philadelphia, PA April, 1995 Pellock JM: New Antiepileptic "Mix and Match" American Academy
of Pediatrics (invited), Philadelphia, PA, April, 1995. Pellock JM: New Horizons in Neurology: Epilepsy Medication American
Academy of Pediatrics (invited) Philadelphia, PA April, 1995 Pellock JM: Safety and Tolerance of Intramuscular Fosphenytoin
(Cerebyx®) in Patients Requiring a Loading Dose of Phenytoin. American Academy
of Neurology, Seattle, Washington, May, 1995. Garnett WR, Kugler AR, O'Hara KA, Driscoll SM, Pellock JM: Pharmacokinetics
of Fosphenytoin and Phenytoin Following Intramuscular Administration of Fosphenytoin
Substituted for Oral Phenytoin in Epileptic Patients, American Academy of Neurology,
Seattle, WA, May, 1995 Pellock JM: (course 343) Management of Epilepsy in Children, in
Clinical Epilepsy, American Academy of Neurology, Seattle, WA May, 1995 Pellock JM: (course 177) Epilepsy Case Studies, Faculty, American
Academy of Neurology, Seattle, WA May, 1995. Pellock JM: (course 315) Pediatric Epilepsy Case Studies: Treatment
Controversies. Chairman American Academy of Neurology, Seattle, WA May, 1995. Pellock JM: Seizures and Epilepsy; Classification and Diagnosis.
Epilepsy Association of Washington, course for primary care physicians. Seattle,
WA May, 1995. Pellock JM: Pediatric Indication for new AEDs in "Epilepsy: What
is the Place New Drugs?" (invited; seminar) American Academy of Neurology, Seattle
WA, May, 1995. Pellock JM: The Pediatric Patient and AED Therapy, Merritt Putnam
Epilepsy Update: A postgraduate committee on the clinical management of epilepsy
and seizures. Seattle, WA May 6, 1995. Pellock JM: Seizures and Treatment, Practical Neurology for the
Generalist Course, American Academy of Neurology, Seattle Washington, May, 1995. Pellock JM: Twin Studies and the Genetics of the Epilepsies: The
Epilepsies: An overview. Eighth International Congress on Twin Studies, Richmond,
VA, May, 1995. Pellock JM: Epilepsy Syndromes (Infancy, Childhood and Adolescence).
Southern Clinical Neurological Society, Montgomery, TX, June 1995. Pellock JM: The Ketogenic Diet and Other Treatment Options for
Children with Seizures. Carolinas Epilepsy Center, Charlotte, NC, June 1995. Pellock JM: The Medical and Surgical Management of Children with
Seizure Disorder. Carolinas Epilepsy Center, Charlotte, NC, June 1995. Pellock JM: Maximizing the Efficacy of New AEDs. Parke-Davis Regional
Consultants Meeting, Carlsbad, CA, July 1995. Pellock JM: The Role of Current AEDs. Advances in Epilepsy Conference,
Lake Geneva, WI, August 1995. Pellock JM: Current Role of Felbamate in Epilepsy Therapy. 21st
International Epilepsy Congress, Sydney, Australia, September 1995. Pellock JM, Corey LA: Epidemiological-Based Twin Studies of Epilepsy.
21st International Epilepsy Congress, Sidney, Australia, September 1995. Pellock JM: The Efficacy and Safety of Lamotrigine as Add-on Therapy.
21st International Epilepsy Congress, Sidney, Australia, September 1995. Pellock JM: New AEDs in Pediatric Epilepsy, Merritt-Putnam. Epilepsy
seminars for Child Neurology Residents and Fellows, Baltimore, MD, October 1995. Shinnar S, Pellock JM, Moshe SL, et al: In Whom does Status Epilepticus
Occur: Age Related Differences in Children. Child Neurology Society, 24th Annual
Meeting, Baltimore, MD, October 1995. Miller LL, Corey LA, Pellock JM, Garnett JM, Delorenzo RJ. Genetic
factors and status epilepticus: Verification of twin study findings in children.
Child Neurology Society, 24th Annual Meeting, Baltimore, MD, October 1995. Pellock JM: Role of Current AEDs. Recent Advances in the Diagnosis
and Treatment of Epilepsy. Duke University, October 1995. Pellock JM: New AEDs in Children. Epileptology. Comprehensive
Review with Practical Exercises. Hilton Head, SC, November 1995. Pellock JM: Epilepsy and the Multiple Handicap. Epilepsy Management
and Neurobehavior. Phoenix, AZ, November 1995. Pellock JM: Gabapentin: Clinical Efficacy and Safety. 14th Annual
Meeting of the Greek Neurology Society, Athens, Greece, November 1995. Pellock JM: Diagnosis and Treatment of ADHD in Adolescents and
Young Children. U.S. Psychiatric and Mental Health Congress, New York, NY, November
1995. Pellock JM: New Concepts in the Pathogenesis of Acquired and Inherited
Epilepsy. American Epilepsy Society, Baltimore, MD, December 1995. Pellock JM: Use of New Antiepileptic Drugs in Children, in: Epilepsy
in Children and Young Adults: Controversies and Recent Advances (Annual Course).
American Epilepsy Society, Baltimore, MD, December 1995. Shinnar S, Pellock JM, Berg AT, et al: An Inception Cohort of
children with Febrile Status Epilepticus: cohort Characteristics and Early Outcomes.
American Epilepsy Society, Baltimore, MD, December 1995. Pellock JM: Practice Habits of Healthcare Providers Treating Patients
with Epilepsy. American Epilepsy Society, Baltimore, MD, December 1995. Watemberg NW, Pellock JM: Efficacy and Tolerability of High-Dose
Gabapentin Add-on Therapy in Children and Adults. American Epilepsy Society,
Baltimore, MD, December 1995. Pellock JM: Neurontin and Cerebyx: Pediatric Considerations. Parke-Davis
Merritt-Putnam Epilepsy Speakers Bureau Meeting, Palm Beach, FL, January 1996. Pellock JM: Pediatric Trials: Practical Issues, Special Populations
and Trial Design. Antiepileptic Drug Trials III, Charleston, SC, March 1996. Pellock JM: Point-Counterpoint: Should We Continue Seizure Types
for Broader FDA Indications? (pro). Antiepileptic Drug Trials III, Charleston,
SC, March 1996. Pellock JM: A Multicenter, Randomized, Double-Blind, Comparative
Study of Gabapentin (CL-945) Administered as an Initial Dosage of 900 mg/day
Versus a Dosage Titrated to 900 mg/day over 3 Days. American Academy of Neurology,
48th Annual Meeting, San Francisco, CA, March 1996. Miller LL, Pellock, JM, Delornzo RJ, Garnette L, Corey LA: The
possible influence of sensitivity genes in join occurrence of status epilepticus
and seizures in families. American Academy of Neurology, 48th Annual Meeting,
San Francisco, CA, March 1996. Pellock JM: Felbamate: Current Practice Opinions. American Academy
of Neurology, 48th Annual Meeting, San Francisco, CA, March 1996. Pellock JM: Status Epilepticus in Children (Course on Status Epilepticus).
American Academy of Neurology, San Francisco, CA, March 1996. Pellock JM: Pediatric Epilepsy Case Studies (Course Chair and
Presenter). American Academy of Neurology, 48th Annual Meeting, San Francisco,
CA, March 1996. Pellock JM: Clinical Epilepsy II: Children and Adolescents. American
Academy of Neurology, 48th Annual Meeting, San Francisco, CA, March 1996. Pellock JM: Pediatric Issues in Epilepsy. Medical Education Systems,
Inc. Lecture Series, Chicago, IL-April 17-18, Detroit, MI - April 24-25, Minneapolis,
MN - May 1, 1996. Pellock JM: New Directions in Acute Seizure Therapy. Medical Education
Programs, Ltd., Palm Beach, FL, June 28-30, 1996. Pellock JM: Epilepsy Management and Quality of Life. Ciba Neuroscience
Programs, Universal City, CA. August 8-11, 1996. Pellock JM: What Do We Do With Felbamate Today? Second European
Congress of Epileptology. The Hague, The Netherlands, September 1-5, 1996. Pellock JM, Fisher RS, Penovich PE, et. al.: A Multicenter, Randomized,
Double-Blind, Comparative Dose-Initiation Study of Gabapentin in Adolescents.
Child Neurology Society Annual Meeting, Minneapolis, MN, September 26-28, 1996. Pellock JM, et. al.: Advances in Pediatric Epilepsy Research,
Satellite Symposium sponsored by Albert Einstein College of Medicine of Yeshiva
University. Child Neurology Society Meeting, Minneapolis, MN, September 28,
1996. Penovich PE, Fisher RS, Pellock JM, et al.: A Multicenter, Randomized,
Double-Blind, Comparative Dose-Initiation Study of Gabapentin (CI-945) in the
Elderly. American Epilepsy Society Meeting, San Francisco, CA, December 5-11,
1996. Pellock JM, Pixton GC, Sommerville KW: Reduction of Complex Partial
Seizures in Tiagabine After Prior Use of Other Gabaergic Antiepilepsy Drugs.
American Epilepsy Society Meeting, San Francisco, CA, December 5-11, 1996. Pellock JM: Pediatric Epilepsy. TOPScholar Symposium. American
Epilepsy Society Meeting, San Francisco, CA. December 5-11, 1996. Pellock JM: Treatment of Age-Specific Seizure Disorders. For AES
Program: Maturational Aspects of the Epilepsy Process. American Epilepsy Society
Meeting. December 5-11, 1996. Pellock JM: Multi-disciplinary Approach to a Child with Neurologic
Problems. Main Speaker. 18th Post-Graduate Course in Pediatrics. University
of the East, Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines.
January 29-31, 1997. Pellock JM: New Aspects in the Management of Epilepsy. New Aspects
in Neurology. Philippine Neurological Association Manila, Philippines. January
29, 1997. Pellock JM: New anticonvulsant: Gabapentin in Special Populations.
Portuguese Epilepsy Congress, Satellite Symposium, Coimbra, Portugal. March
20, 1997. Pellock JM: Gabapentin in Children. Satellite to the Fifth Academic
Congress of the Ibero-American Pediatric Neurology Society, Valencia, Spain.
March 21, 1997. Towne AR, Boggs JG, ... Pellock JM, et al: Mortality of Status
Epilepticus in Community and University Hospital Settings. 49th Annual Meeting
of the American Academy of Neurology, Boston MA, April 15, 1997. DeLorenzo RJ, Towne AR, ... Pellock JM: Non-Convulsive Status
Epilepticus Following the Clinical Control of Convulsive Status Epilepticus.
49th Annual Meeting of the American Academy of Neurology, Boston MA, April 15,
1997. Boggs JG, Marmarou A, ... Pellock JM, et al: Hemodynamic Monitoring
Prior to Death in Status Epilepticus. 49th Annual Meeting of the American Academy
of Neurology, Boston MA, April 15, 1997. Morton LD, Gutcher G, Pellock JM, DeLorenzo RJ: Population-Based
Incidence of Neonatal Status Epilepticus in Richmond, Virginia. 49th Annual
Meeting of the American Academy of Neurology, Boston MA, April 17, 1997. Pellock JM: Meta-Analysis of Adjunctive Tiagabine Efficacy and
Safety in Adolescents in Controlled Studies. 49th Annual Meeting of the American
Academy of Neurology, Boston MA, April 17, 1997. Pellock JM: Faculty, Seminar Director for Pediatric Epilepsy Case
Studies. American Academy of Neurology, Boston, MA, April 13-17, 1997. Pellock JM: Treatment of Epilepsies, Neurophysiology for the Initiated:
A Refresher Course. Albert Einstein College of Medicine of Yeshiva University,
Bronx, NY, May 2-4, 1997. Pellock JM: Infants and Childhood Seizure Syndromes: Treatment
Choices-How About Surgery? Epilepsy Update, A Postgraduate Course on the Clinical
Management of Epilepsy and Seizures, Pasadena, CA, May 15-18, 1997. Pellock JM: Twins, Families, and Epilepsy. 25th Annual Hans Berger
Symposium, May 20, 1997. Pellock JM: Epilepsy-Special Situations, Using the New Drugs in
Pediatric Patients. Grove Park Family Neurology Update, Asheville, NC, June
6-8, 1997. Pellock JM: Current Concepts in Child Neurology: Epileptology
and Seizure Pharmacology-New Antiepileptic Drugs; Selecting Appropriate Studies
for a Child with Seizure Disorders; and Advances in Pediatric Epileptology and
Cognitive Disorders-Recognition and Management of ADHD and Attention Deficit,
Hyperactive Disorder and the Neurologist. Childrens Hospital, San Diego, CA,
June 13-15, 1997. Pellock JM: Benzodiazepines in the Management of Acute Seizure
Episodes. The Role of Benzodiazepines in Acute Seizures, satellite symposium
preceding International Epilepsy Congress, Dublin, Ireland, June 28, 1997. Pellock, JM: Meet The Expert: Update on Pediatric Epilepsies.
International Epilepsy Congress, Dublin, Ireland, June 30, 1997. Pellock JM, Corey LA: The Virginia Registry. Workshop on Twin
Studies in Epilepsy, ILAE, International Epilepsy Congress, Dublin, Ireland,
June 28, 1997. Corey LA, Pellock JM, Boggs JG, and Miller LL: Febrile Seizures
in a Virginia Twin Population. Poster Presentation, International Epilepsy Congress,
Dublin, Ireland, July 2, 1997. Pellock JM: Dealing with Seizure Disorders in Persons with Developmental
Disabilities. Dimensions in Developmental Disabilities III: At The Crossroads,
San Jose, CA, September 25, 1997. Shields WD, Kerrigan JF, ... Pellock JM, Morton LD, et al: Ganaxolone
in the Treatment of Refractory Infantile Spasms. Poster Presentation, American
Neurological Association, San Diego, CA, September 28-October 1, 1997. Morton LD, Pellock JM, Gilman JT, et al: Fosphenytoin Pharmacokinetics
and Safety in Children. Poster Presentation, American Neurological Association,
San Diego, CA, September 28-October 1, 1997. Pellock JM: Efficacy Studies, Indications, Rational Sequencing;
Recent Advances in Pediatric Epilepsy; and Status Epilepticus. An Update on
the Management of Epilepsy, Indiana University School of Medicine, Indianapolis,
IN, October 11, 1997. Pellock M: Epilepsy and Other Neurologic Disorders in Adults with
Mental Retardation. Care of the Aging Adult with Mental retardation, Johns Hopkins
Medical Institutions, Baltimore, MD, October 20, 1997. Pellock JM: Chairman, Epilepsy Seminar for Child Neurology Residents
and Fellows. Parke-Davis, MCV/VCU, Phoenix, AZ, October 28-29, 1997. Pellock JM: New AEDs in Pediatric Epilepsy, Epilepsy Seminar for
Child Neurology Residents and Fellows. Parke-Davis, MCV/VCU, Phoenix, AZ, October
28-29, 1997. Pellock JM: Visiting Professor, Meet the Professor. Child Neurology
Society Annual Meeting, Phoenix, AZ, October 30-November 1, 1997. Pellock JM: Status Epilepticus: What’s New in Outcome and
Therapy. American Academy of Pediatrics Annual Meeting, New Orleans, LA, November
1-5, 1997. (invited) Alehan FK, Watemberg NM, Pellock JM: Correlation Between Gabapentin
Serum Levels and Doses in Children. American Epilepsy Society Annual Meeting,
Boston, MA, December 5-10, 1997. Pellock JM, Deaton R, Sommerville W: Use of Tiagabine as Long-Term
Therapy of Complex Partial Seizures in Adolescents. American Epilepsy Society
Annual Meeting, Boston, MA, December 5-10, 1997. Graf WD, Pellock JM, Duchowny M, et al: Lamictal is Effective
for Add-On Treatment of Partial Seizures in Children and Adolescents. American
Epilepsy Society Annual Meeting, Boston, MA, December 5-10, 1997. Morton LD, Pellock JM, Maria BL, et al: Fosphenytoin Safety and
Pharmacokinetics in Children. American Epilepsy Society Annual Meeting, Boston,
MA, December 5-10, 1997. Sawin K, Pellock JM, Metzger S: Adolescents with Epilepsy: Perception
of Psychosocial Competency. American Epilepsy Society Annual Meeting, Boston,
MA, December 5-10, 1997. Elixhauser A, Leidy NK, Rentz AM, Beach RL, Pellock JM, et al:
Telephone Validation of the Quality of Life in Epilepsy Inventory (QOLIE-89).
American Epilepsy Society Annual Meeting, Boston, MA, December 5-10, 1997. Pellock JM: Efficacy of New AEDs in Catastrophic Epilepsies. Symposium
- Spectrum of Activity of New AEDs: Which Patients Will Benefit? American Epilepsy
Society Symposium at the Annual Meeting, Boston, MA, December 8, 1997. Pellock JM: Multiply handicapped: medical management of epilepsy.
25th Annual Southern Clinical Neurological Society Meeting, Advances in Neurology,
Huatulco, Mexico, January 19, 1998. Pellock JM: First unprovoked seizure. 19th Annual Child Neurology
Post-Graduate Course, Miami Children’s Hospital, Miami, FL, March 30, 1998. Pellock JM: Status Epilepticus. 19th Annual Child Neurology Post-Graduate
Course, Miami Children’s Hospital, Miami, FL, March 30, 1998. Pellock JM: Pediatric epilepsy case studies. American Academy
of Neurology Annual Meeting, May 2, 1998. Pellock JM: Update on new and forthcoming antiepileptic drugs.
Hans Berger Symposium, Richmond, VA, May 19, 1998. Pellock JM: Reported role of Neurontin in pediatrics. Neurontin
Symposium, Cannes, France, June 5, 1998. Corey LA, Pellock JM, Miller L: Febrile seizure and epilepsy in
Virginia-born twins, 9th International Congress on Twin Studies, Helsinki, Finland,
June 6, 1998. Pellock JM: Medical Treatment of Focal Epilepsies. Comprehensive
Epilepsy Course, Cleveland Clinic, Cleveland, OH, June 21, 1998. Pellock JM: Epilepsy today, you still need a clinical diagnosis.
Fritz E. Dreifuss Memorial Lecture Series, Epilepsy Association of Virginia
and University of Virginia Department of Neurology, Charlottesville, VA, August
28, 1998. Pellock JM: Critical issues in the treatment of febrile seizures.
American Academy of Pediatrics Annual Meeting, San Francisco, CA, October 16,
1998. Kriel RL, Cloyd JC, Pellock JM, et al: Rectal diazepam gel (Diastat)
in the treatment of children with acute repetitive seizures. Child Neurology
Society Annual Meeting, Montreal, Quebec, Canada, October 21-24, 1998. Pellock JM: Management of intractable childhood seizures. Symposium
II Epilepsy: Practical Aspects. Child Neurology Society Annual Meeting, Montreal,
Quebec, Canada, October 22, 1998. Pellock JM: Felbamate: new antiepileptic drugs: basic science
and clinical use in children and adults, American Epilepsy Society Annual Course,
San Diego, CA, December 6, 1998. Alehan FK, Watemberg NM, Pellock JM: Long-term use of gabapentin
in pediatric epilepsy. American Epilepsy Society Symposium at the Annual Meeting,
San Diego, CA, December 6-9, 1998 Bourgeois B, Brown LW, Pellock JM, et al: gabapentin (Neurontin)
monotherapy in children with benign childhood epilepsy with centrotemporal spikes
(BECTS): a 36-week, double-blind, placebo-controlled study. American Epilepsy
Society Symposium at the Annual Meeting, San Diego, CA, December 6-9, 1998 O’Hara KA, Hickman RW, Driscoll-Bannister, Pellock JM: Assessment
of prenatal counseling for women with epilepsy. American Epilepsy Society Symposium
at the Annual Meeting, San Diego, CA, December 6-9, 1998 Corey LA, Pellock JM, DeLorenzo RJ: Estimation of prevalence of
status epilepticus in a Virginia twin population. American Epilepsy Society
Symposium at the Annual Meeting, San Diego, CA, December 6-9, 1998 Pellock JM, Mitchell WG, Cloyd JC: Diastat (diazepam rectal gel)
in the treatment of acute repetitive seizures in adults. American Epilepsy Society
Symposium at the Annual Meeting, San Diego, CA, December 6-9, 1998 Knapp LE, Morton LD, Pellock JM, et al: Fosphenytoin safety and
pharmacokinetics in pediatric patients. American Epilepsy Society Symposium
at the Annual Meeting, San Diego, CA, December 6-9, 1998 Morton LD, Watemberg NM, ...Pellock JM, et al: Long-term outcome
of status epilepticus in the first year of life. American Epilepsy Society Symposium
at the Annual Meeting, San Diego, CA, December 6-9, 1998. Pellock JM: Treatment of prenatal, neonatal and childhood seizures,
Southern Clinical Neurological Society Annual Meeting, Curaçao, Netherlands
Antilles, January 19, 1999. Pellock JM: Genetics of Epilepsy. Minisymposium - Biology and
Genetics of Epilepsy. American Academy of Clinical Neurophysiology Annual Meeting
and Course Review, Sante Fe, NM, January 29, 1999. Pellock JM: The complications of the newer antiepileptic drugs,
Pediatric Epilepsy Roundtable, Pam Springs, CA, February 11, 1999. Pellock JM: Topamax in children, Congress of the Portugese League
Against Epilepsy, Portugal, March 5, 1999. Pellock JM: Initiation and titration of new antiepileptic drugs
and rational polytherapy, Epilepsy in Developmental Disabilities, New York Medical
College, Valhalla, NY, March 17, 1999. Pellock JM: Acute Seizures, Grand Rounds, Children’s Hospital
Oakland, Oakland, CA, March 23, 1999. Pellock JM: New Anticonvulsants, Children’s Hospital Oakland,
Oakland, CA, March 23, 1999. Pellock JM: Pediatric Epilepsy Case Studies, American Academy
of Neurology Annual Meeting, Toronto, Canada, April 18, 1999. Pellock JM: Tiagabine (Gabitril) experience in children, Sanofi
International Symposium on Epilepsy Management, Marrakech, Morocco, April 29,
1999. Pellock JM: Update on new antiepileptic drugs, Hans Berger Symposium,
Richmond, VA, May 18, 1999. Pellock JM: Single-Dose Pharmacokinetics Of Levetiracetam in Pediatric
Patients with Partial Epilepsy, American Epilepsy Society, 53rd Annual Meeting,
Orlando, FL, December 1999. Pellock JM: Safety and Tolerability of Intravenous Valproate (Depacon
™) Administered at Rapid Infusion Rates in Pediatric Pateints. American
Epilepsy Society Meeting, 53rd Annual Meeting, Orlando, FL, December 3-8, 1999. Pellock JM: Verification of Twin Registry Questionnaires for Epilepsy,
American Epilepsy Society, 53rd Annual Meeting, Orlando, FL, December 1999. Pellock JM: Co- Chair Symposium: Southern Clinical Neurological
Society Meeting, Ixtapa, Mexico, January 17, 2000. Pellock JM: New AEDs -What’s in the future. Southern Clinical
Neurological Society Meeting, Ixtapa, Mexico, January 17, 2000. Pellock JM: Chair: Epilepsy Symposium, Southern Clinical Neurological
Society Meeting, Ixtapa, Mexico, January 17, 2000. Pellock JM: Felbamate: Adverse effects and monitoring. Southern
Clinical Neurological Society Meeting, Ixtapa, Mexico, January 17, 2000. Pellock JM: AEDs - special use in children. Southern Clinical
Neurological Society Meeting, Ixtapa, Mexico, January 17, 2000. Pellock JM: Critical Issues in the Use of Antiepileptic Drugs,
Southern Clinical Neurological Society Meeting, Ixtapa, Mexico, January 17,
2000. Pellock JM: New Drug Selection and How to Use Them. Southern Clinical
Neurological Society 5th Annual NeuroScience Update, Crested Butte, Colorado,
March 8-13, 2000. Pellock JM: New AEDs in Children: Which Should We Use? Dr. Ruth
W. Baldwin Lecture and Visiting Professorship, University of Maryland School
of Medicine, Baltimore, MD April 26, 2000. Pellock JM: New Antiepileptic Drugs, Children and Adolescence,
Southern Clinical Neurological Society 5th Annual NeuroScience Update, May 26-29,
2000. Pellock JM: New Treatments for an Old Disorder: Pediatric Epilepsy.
Robert M. Eiben, MD, Visiting Professorship, Cleveland, Ohio, May 11-12, 2000. Pellock JM: What Pediatricians Need to Know about Anticonvulsives.
Current Concepts in Child Neurology, Children’s Hospital and Health Center,
San Diego, CA, June 16-18, 2000, Guest speaker. Pellock JM: Visiting Professorship, Kapiolani Medical Center,
Honolulu, Hawaii, June 18-25, 2000. Pellock JM: Children and the New Generation of AEDs From Felbamate
to Zonisamide. Southern Clinical Neurological Society 10th Annual Big Cedar
Neuro-Science Update, Ridgedale, Missouri, July 27-30, 2000. Pellock JM: Pediatric experience in New AEDs. Epilepsy in Children.
Third Russian-American Symposium on the Clinical and Social Aspects of Epilepsy,
Moscow, Russia, August 27-September 1, 2000. Pellock JM: Clinical Approach to the Child with Intractable Epilepsy,
Northeast Regional Epilepsy Group Symposium, Rye Town, NY, Sept. 23, 2000, Invited
Speaker. Pellock JM: Pediatric Epilepsy 2000: What is Really New? First
Annual Pediatric Neurosciences Symposium, Southern Illinois University, Springfield,
IL, Guest Faculty. Glauser TA, Pellock JM. Efficacy of Zonisamide in Pediatric Epilepsy:
Experience in Japanese Subjects. Child Neurology Society Meeting, St. Louis,
MO, October 26, 2000. Pellock, JM, Glauser TA. Safety of Zonisamide in Pediatric Epilepsy:
The Japanese Experience. Child Neurology Society Meeting, St. Louis, MO, October
26, 2000. Pellock JM. New Choices for Treatment of Infantile Partial Seizures,
Children’s Memorial Hospital Special Symposium, Chicago, Il, November 9-10,
2000, Invited Speaker. Pellock, JM, Marmarou A and the International Epilespy Consortium.
Response to and Attitudes Toward Zonisamide Therapy: Preliminary Results from
the EASE Program. American Epilepsy Society, 54th Annual Meeting, Los Angeles,
CA, December 3, 2000. Pellock JM. The Treatment of Childhood Epilepsy in the U.S. -
New AEDs, New Decisions. Okayama, Japan, Visiting Professor, February 2-6, 2001. Pellock JM. Acute Seizures and Status Epilepticus: a Modern Approach..
Okayama, Japan, Visiting Professor, February 2-6, 2001. Pellock JM. Status Epilepticus in Children - Is It Really Benign?
Okayama, Japan, Visiting Professor, February 2-6, 2001. Pellock, JM. Approach to the Patient Who Fails the First Antiepileptic
Drug. Evolving Directions in the Management of Epilepsy. Joint conference of
the NINDS (AES, AAN, EF) Bethesda, Maryland, March 5-6, 2001. Pellock JM. Pediatric Epilepsy Case Studies. Course Director.
American Academy of Neurology, Annual Meeting, Philadelphia, PA. May 5-11, 2001. Articles and Papers Published Kendig EL, Pellock JM, Becker SM, Kellett GN, II: The prevalence
of smoking among adolescents with primary tuberculosis. Chest 1974;6:100. Pellock JM, Berenberg R, DiMauro S, et al: Lumping or splitting?
Ophthalmoplegia plus or Kearns-Sayre Syndrome Trans- American Neurological Association
1976:133-7. Pippenger CE, Pellock JM, Gold AP: Antiepileptic drug concentrations
in children on multiple therapy. Antiepileptic Drug Monitoring. London: Pittman
Medical, 1977:282-6. Berenberg R, Pellock JM, DiMauro S, et al: Lumping or splitting?
Ophthalmoplegia plus or Kearns-Sayre Syndrome. Ann Neurol 1977;1:37-54. Pellock JM, DiMauro S, Behrens M, et al: Kearns-Sayre syndrome
and hypoparathyroidism. Ann. Neurol. 1978;3:455-8. DiChiro G, Arimitsu T, Pellock JM, Landers RD: Periventricular
leukomalacia related to neonatal anoxia: Recognition by computed tomography.
J Comput Tomogr 1980;2:352-5. Pellock JM, Kleinman PK, McDonald BM, Wilson D: Childhood hypertensive
stroke with neurofibromatosis. Neurology 1980;30:656-9. Pellock JM: Recent developments in the treatment of epilepsy.
Part I: Diagnosis and Treatment. Delaware Medical Journal, 1981;53:305-12. Pellock JM: Recent developments in the treatment of epilepsy.
Part II: Modern Therapeutic Methods. Delaware Medical Journal 1981;53:361-4. Hamilton RA, Garnett WR, Kline BJ, Pellock JM: The effect of food
on valproic acid absorption. Am J Hosp Pharm 1981;38:1490-3. Carter B, Garnett WR, Pellock JM, et al: Effect of antacids on
phenytoin bioavailability. Therap Drug Monitor 1981;3:333-40. May CA, Garnett WR, Small RE, Pellock JM: Effects of three antacids
on the bioavailability of valproic acid. Clinical Pharmacy 1982;244-7. Phelan MC, Pellock JM, Nance WE: Discordant expression of fetal
hydantoin syndrome in heteropaternal dizygotic twins. New Engl J Med 1982;307:99-101. Marsh TD, Garnett WR, Poynor WJ, Pellock JM: Effects of exercise
on valproic acid pharmacokinetics. Clin Pharmacy 1983;2:62-4. Flannery DB, Pellock JM, Bousounis D, et al: Nonketotic hyperglycemia
in two retarded adults: A mild form of infantile Nonketotic hyperglycemia. Neurology
1983;33:1064-6. Antunes JL, Sharer LR, Pellock JM: Occipital encephalocele. A
case of conjoined twinning: Neurosurgery 1983;13:703-7. Pugh CB, Garnett WR, Poynor WJ, Pellock JM: Single dose model
for predicting steady-state valproic acid serum concentrations in seizure patients.
Clin Pharm 1984;3:643-9. Mulroy JJ, Mickell JJ, Tong TK, Pellock JM: Postictal pulmonary
edema in children: Neurology 1985;35:403-5. Pellock JM, Howell J, Kendig L, Baker H: Pyridoxine deficiency
in children. Chest 1985;67:658-61. Tarasidis CG, Garnett WR, Kline BJ, Pellock JM: The influence
of time, temperature and tube type on free and total valproic acid levels. Therap
Drug Monitor 1986;8:373-6. Fitzsimmons WE, Garnett WR, Comstock TJ, Pellock JM: Comparison
of the single dose bioavailability and pharmacokinetics of extended phenytoin
sodium capsules and phenytoin oral suspension. Epilepsia 1986;27:464-8. Maas B, Garnett WR, Comstock TJ, Pellock JM: Comparison of the
relative bioavailability and pharmacokinetics of carbamazepine tablets and chewable
tablets formulations. Therap Drug Monitor 1987;9:28-33. Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Pellock JM,
Karnes HT: Effect of two administration schedules of an enteral nutrient formula
on phenytoin bioavailability. Epilepsia 1987;28:713-6. Pellock JM: Carbamazepine side effects in children and adults.
Epilepsia 1987;28(3):S64-S70. Ardinger HH, Atkin JF, Blackston D ... Pellock JM, et al: Verification
of the fetal valproate syndrome phenotype. Am J Med Genetics 1988;29:171-85. Pellock JM: Treatment of Seizures in Childhood. Virginia Medical
1988;115:223-5. Pellock JM, McIntyre HB, Rivera VM: Carbamazepine: A retrospective
usage survey of prescribing and monitoring habits. J Epilepsy 1989;2:169-73.
The Group for the Evaluation of Cinromide in the Lennox-Gastaut
Syndrome (Pellock JM, Garnett WR at MCV): Double-Blind, Placebo-Controlled Evaluation
of Cinromide in Patients with the Lennox-Gastaut Syndrome. Epilepsia 1989;30:422-9. Coniglio AA, Garnett WR, Pellock JM et al: Effect of Acute and
Chronic Terfenadine on Free and Total Serum Phenytoin Concentrations in Epileptic
Patients. Epilepsia 1989;30:611-6. Pellock JM: Efficacy and Adverse Effects of Antiepileptic drugs.
Pediatric Clin N Am 1989;36:435-8. Pugh CB, Garnett WR, Pellock JM: Usefulness of a single dose prediction
model for the determination of long-term maintenance therapy of valproic acid.
Therap Drug Monitoring 1990;11:658-60. Pellock JM: Recent Advances Concerning Status Epilepticus. Int
Pediatrics 1990;5(2):188-95. Pellock JM: Risk Versus Benefits of Antiepileptic Drug Therapy.
Int Pediatrics 1990;5(2):176-80. Pellock JM: The Classification of Childhood Seizures and Epilepsy
Syndromes. Neur Clin 1990;8:619-32. Seetharam, MN, Pellock JM: Risk-Benefit Assessment of Carbamazepine
in Children. Drug Safety 1991;6:148-58. Willmore LJ, Triggs WJ, Pellock JM: Valproate Toxicity: Risk-Screening
Strategies. J Child Neurol 1991;6:3-6 Pellock JM, Willmore LJ: A Rational Guide to Routine Blood Monitoring
in Patients Receiving Antiepileptic Drugs. Neurology 1991;41:961-4. Ramsey RE, Pellock JM, Garnett WR, et al: Pharmacokinetics and
Safety of Lamotrigine (Lamictal) in Patients with Epilepsy. Epilepsy Research
1991;10:191-200. Corey LA, Berg K, Pellock JM, Solaas M, et al: The Occurrence
of Seizures in Virginian and Norwegian Twins. Neurology 1991;41:1433-5. So EL, Lai CW, Pellock J, Mashman J, Brugger A: Safety and Efficacy
of Valproate and Carbamazepine in the Treatment of Complex Partial Seizures.
J Epilepsy 1992;5:149-52. DeLorenzo RJ, Towne AT, Pellock JM, Ko D: Status Epilepticus in
Children, Adults and the Elderly. Epilepsia 1992;33:S15-S25. Pellock JM: Seizures and Epilepsy in Infancy and Childhood. Neurologic
Clin 1993;11:755-75. Salbert BA, Pellock JM, Wolf B: Characterization of Seizures Associated
with Biotinidase Deficiency. Neurology 1993;43:1351-5. Pellock JM: Standard Approach to Antiepileptic Drug Treatment
in the United States. Epilepsia 1994;35:S11-8. Towne AR, Pellock JM, Do D, DeLorenzo RJ: Determinants of Mortality
in Status Epilepticus. Epilepsia 1994;35:27-34. Pellock JM: Role of New Medication in the Treatment of Childhood
Epilepsy. Int Pediatrics 1994;9(2):100-8. Pledger GW, Sackellares JC, Treiman, DM, Pellock JM, et al: Flunarizine
for Treatment of Partial Seizures: Results of a Concentration-Controlled Trial.
Neurology 1994;44:1830-6. Pellock JM: Status Epilepticus in Children: Update and Review.
J Child Neurology 1994;9(2):S27-35. Pellock JM: The Clinical Efficacy of Lamotrigine as an Antiepileptic
Drug. Neurology 1994;44(8):S29-S35. Pellock JM, Boggs JG: Felbamate: A Unique Anticonvulsant. Drugs
of Today 1995;31(1):9-17. Pellock JM: Antiepileptic Drug Therapy in the United States: A
Review of Clinical Studies and Unmet Needs. Neurology 1995; 45(2):S17-24. Garnett WR, Pellock JM: Critical Drug Appraisal: Lamotrigine -
Effective Oral Add-On Therapy. P&T 1995;20:156-70. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG: Epidemiology of
Status Epilepticus. J Clin Neurophys 1995;12:(4)316-25. O'Hara KA, Pellock JM Lamotrigine in Refractory Epilepsy: The
Effect of Dosage Titration on Efficacy and Adverse Effects. Search on Epilepsy
1995;2. Devinsky O, Leppik I, Wilmore LJ, Pellock JM, et al: Safety of
Intravenous Valproate. Ann Neurol 1995;38(4):670-4. Wilder BJ, Campbell K,...Pellock JM: Safety and Tolerance of Multiple
Doses of Intramuscularly Administered Fosphenytoin (Cerebyx®) Substituted
for Oral Phenytoin (Dilantin®) in Epilepsy or Neurosurgery. Arch Neurol
1996, 53(8):764-8. Brodie MJ, Pellock JM: Taming the Brain Storms: Felbamate Updated.
Lancet 1995;346(3980):918-9. Morton LD, Pellock JM: Diagnosis and Treatment of Epilepsy in
Children and Adolescents. Drugs 1996;51(3):399-414. DeLorenzo RJ, Hauser WA,...Pellock JM, et al: A Prospective Population-Based
Epidemiological Study of Status Epilepticus in Richmond, Virginia. Neurology
1996;46:1029-35. Pellock JM: Utilization of New Antiepileptic Drugs in Children.
Epilepsia 1996;37(1):S66-S73. Pellock JM: Fosphenytoin Use in Children. Neurology 1996;46(6):S14-S16. Pellock JM: Seizure Therapy in the Pediatric Setting. P&T
1996;21(5S):21S-23S. Pellock JM: Formulary Report: Issues in the Management of Acute
Seizures. P&T 1996;21(5S). Pellock JM, Hunt PA: A Decade of Modern Epilepsy Therapy in Institutionalized
Mentally Retarded Patients. Epilepsy Research 1996;25:263-8. Pellock JM: Pharmacological Treatment of Children with ADHD Syndrome:
When to Start and to Stop. Int Pediatrics 1996;11(5):295-303. Pellock JM: Pediatric Epilepsy in the 1990s. Seminars in Pediatric
Neurology 1997;4(1):1-2. Pellock JM, Watemberg N: New Antiepileptic Drugs in Children:
Present and Future. Seminars in Pediatric Neurology 1997;4(1):9-18. Morton LD, Rizkallah E, Pellock JM: New Drug Therapy for Acute
Seizure Management. Seminars in Pediatric Neurology 1997;4(1):51-63. Driscoll SM, Morton, LD, Pellock JM: New Antiepileptic Drugs:
Case Studies. Seminars in Pediatric Neurology 1997;4(1):64-7. Watemberg NM, Pellock JM: Use of new antiepileptic drugs in children:
update. Int Pediatrics 1997;12(1):6-14. Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, et al:
Intramuscular fosphenytoin (Cerebyx®) in patients requiring a loading dose
of phenytoin. Epilepsy Research 1997; 28(3):181-8. Shinnar S, Pellock JM, Moshe SL et al: In whom does status epilepticus
occur: age-related differences in children. Epilepsia 1997;38(8):907-14. Ramsey RE, Uthman B, Leppik IE, Pellock JM, et al: The tolerability
and safety of valproate sodium injection given as an intravenous infusion. Journal
of Epilepsy 1997;10(4):187-93. Pellock JM: Editorial: Lamotrigine. J Child Neurol 1997;12(Suppl):S1. Pellock JM: Overview of lamotrigine and the new antiepileptic
drugs: the challenge. J Child Neurol 1997;12(Suppl):S48-S52. Pellock JM, Brodie MJ: Editorial: Felbamate: 1997 update. Epilepsia
1997;38(12):1261-4. Miller LL, Pellock JM, DeLorenzo RJ, et al: Univariate genetic
analyses of epilepsy and seizures in a population-based twin study: the Virginia
twin registry. Genetic Epidemiology 1998;15(1):33-49. Dreifuss FE, Pellock JM (eds): The role of benzodiazepines in
acute seizures. Proceedings of a satellite symposium, 22nd International Epilepsy
Congress, Dublin, Ireland, June 28, 1997. Epilepsia 1998;39(Suppl 1). Pellock JM: Management of acute seizure episodes. Epilepsia 1998;39(Suppl
1):S28-S35. Corey LA, Pellock JM, Boggs JG, et al: Evidence for a genetic
predisposition for status epilepticus. Neurology 1998;50:558-60. Garnett WR, Levy B, McLean AM,...Pellock JM, et al: Pharmacokinetic
evaluation of twice-daily extended-release carbamazepine and four-times-daily
immediate-release carbamazepine in patients with epilepsy. Epilepsia 1998: 39(3):274-9. Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, et al: A comparison
of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med
1998;26:1869-75 . Boggs JG, Marmarou A, Agnew JP,...Pellock JM, et al: Hemodynamic
monitoring prior to and at the time of death in status epilepticus. Epilepsy
Research 1998;31:199-209. Pellock JM: Treatment of seizures and epilepsy in children and
adolescents. Neurology 1998;51(Suppl 4):S8-S14. Pellock JM, Morton LD, Watemberg NM: New antiepileptic drugs therapy
for children. The Neurologist 1998;4(5):S16-S22. Pellock JM: Editorial: Acute seizures in children: an overview.
J Child Neurol 1998;13(Suppl 1):S1-S2. Pellock JM (ed): Management of acute seizures in children. J Child
Neurol 1998;13(Suppl 1). Morton LD, Pellock JM: Treatment options for acute seizure care,
use of new formulations. CNS Drugs 1998;10:405-16. Pellock JM: Use of midazolam for refractory status epilepticus
in pediatric patients. J Child Neurol 1998;13:581-7. Leidy NK, Elixhauser A, Rentz AM, Beach R, Pellock JM, et al:
Telephone validation of the quality of life in epilepsy inventory-89. Epilepsia
1999;40:97-106. Alehan FK, Morton LD, Pellock JM: Treatment of absence status
with intravenous valproate. Neurology 1999;52(4):889-90. Kriel RL, Cloyd JC, Pellock JM, et al: Rectal Diazepam gel for
treatment of children with acute repetitive seizures. Ped Neurology 1999 Apr;20(4):282-8. Miller LL, Pellock JM, Boggs JG, DeLorenzo RJ, Meyer JM, Corey
LA. Epilepsy and seizure occurrence in a population based sample of Virginian
twins and their families. Epilepsy Res. 1999 Apr;34(2-3):135-43. Pellock JM: Emergency room management of status epilepticus with
Midazolam, P&T 1999. [submitted] Pellock JM: Use of the new antiepileptic drugs in paediatrics.
Broadening the spectrum of clinical uses of antiepileptic drugs. 2000 International
Congress and Symposium Series 241. Pellock JM and Appleton R. Use of New Antiepileptic Drugs in the
Treatment of Childhood Epilepsy. Epilepsia 1999;40(suppl.6):S29-38. Alehan, FK, Morton LD, Pellock JM. The utility of electroencephalogram
in the pediatric emergency department. J Child Neuro, in press 2001. Pellock, JM. Managing Pediatric Epilepsy Syndromes With New Antiepileptic
Drugs. Pediatrics 1999;104(5):1106-1116. Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J. Casale E,
Womble G, Risner M, Manasco P. A placebo-controlled trial of lamotrigine add-on
therapy for partial seizures in children. Neurology 1999;53:1724-1731. Pellock JM. Felbamate. Epilepsia 1999;40(suppl 5);S57-62. Kriel RL, Cloyd, JC, Pellock JM, Mitchell WG, Cereghino JJ, Rosman
NP, and the North American Diastat Study Group. Rectal Diazepam Gel for Treatment
of Acute Repetitive Seizures. Pediatr Neurol 1999;20:282-288. Pellock JM. New delivery systems in the treatment of epilepsy:
will they help promote compliance? Hospital Medicine 1999 (8):44-49. Guberman AH, Besag FMC, Brodie MJ... Pellock JM, et al. Lamotrigine-Associated
Rash: Risk/Benefit Considerations in Adults and Children. Epilepsia 40(7):985-991,
1999. Watemberg N, Willis D, Pellock JM. Encephalopathy as the presenting
symptom of Hashimoto’s thyroiditis. J Child Neurol. 2000 Jan;15(1):66-9. Kriel RL, Clyod JC, Pellock JM. ‘Respiratory depression in
children receiving diazepam for acute seizures; a prospective study". Dev
Med Child Neurol 2000 Jun;42(6):429-30. Pellock JM. Treatment of Epilepsy in the New Millennium. Pharmacotherapy
2000;20:129S-138S). Pellock JM. New antiepileptic drugs: what’s in the future?
Treatment of paediatric epilepsy. In: Medical management of selected neurological
disorders: epilepsy, spasticity and pain. Edited by: Wilder BJ and Pellock JM.
Royal Medicine Press 2000. Morton LD, Pellock JM. Overview of Childhood Epilepsy and Epileptic
Syndromes and Advances in Therapy. Current Pharmaceutical Design 2000, 6:879-900. Pellock JM. Felbamate. In: New Antiepileptic Drugs: Basic Science
and Clinical Use in Children and Adults. Willmore LJ, (ed). Epilepsia 1999;40(supl
5):S57-62. Privitera MD, Devinsky O, Faught RE, Leppik RE, Pellock JM, Schachter
S, Alderfer V, Holdich TAH. A Double-Blind, Placebo-Controlled, Study of Remacemide
Hydrochloride in Patients with Refractory Epilepsy Following Pre-Surgical Assessment.
[submitted 2000]. Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois
BFD, Pellock JM, Morton LD, Monaghan EP. Ganaxolone for treating intractable
infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Research
42 (2000) 133-139. Pellock JM. Treatment of Epilepsy in the New Millennium. Pharmacotherapy
2000;20(8 PT 2): 129S-138S). Pellock JM, Wilder BJ. Issues of quality of life, epilepsy advances
, and evolving role of anticonvulsants. In: Issues of Quality of Life, Epilepsy
Advances, and Evolving Role of Anticonvulsants. Pellock JM and Wilder BJ (eds).
Neurology 55 (5) Supp 1, 2000. Pellock JM, Morton LD. Treatment of Epilepsy in the Multiply Handicapped.
Mental Retardation and Developmental Disabilities Research Reviews, 2000, 6:309-323 Shinnar S, Pellock JM, Berg AT, O’Dell C, Driscoll SM, Maytal
J, Moshe S, DeLorenzo RJ. Short Term Outcomes of Children with Febrile Status
Epilepticus. Epilepsia 42(1):47-53, 2001. Glauser, TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen
CM, Shields WD. Efficacy and safety of levetiracetam in an open-label trial
in children with partial seizures. J Child Neuro [Submitted 2000] Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez
RM, Shields WD. Pharmacokinetic Study of Levetiracetam in Children. Epilepsy
Research [Submitted 2000] Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L and Bernstein
P. Rapid initiation of gabapentin: A randomized, controlled trial. Neurology
2001;56:743-748. Pellock JM. Important Changes in the Treatment of Epilepsy. Article
update. Pharmacotherapy 2001;21(4):517-518. Low NL, Pellock JM: Seizure Disorders in Children. In: Kelly,
VC (ed): Brennemann's Practice of Pediatrics. Chap. 18, Vol. IV, New York: Harper
and Row Publishers, 1976. Low NL, Pellock JM: Seizure Disorders in Children, Update Addendum.
In: Kelly, VC (ed): Brennemann's Practice in Pediatrics, Chap. 18, Vol. IV,
New York: Harper and Row Publishers, 1980. Pellock JM, Low NL: Seizure Disorders. In: Kelly, VC (ed): Practice
of Pediatrics, Chap. 18, Vol. IV, New York: Harper and Row Publishers, 1980. Myer EC, Pellock JM: Disorders of the Nervous System. In: Maurer,
H. (ed): Pediatrics. New York: Churchill Livingstone, 1983. Pellock JM, Myer EC, (eds): Neurologic Emergencies in Infancy
and Childhood. Philadelphia: Harper and Row, 1984. Pellock JM: Status Epilepticus. In: Pellock JM, Myer EC, (eds):
Neurologic Emergencies in Infancy and Childhood. Philadelphia: Harper and Row/Lippincott,
1984. Pellock JM: Seizures and Epilepsy. In: Kelly, VC (ed): Practice
of Pediatrics, Chap. 39, Vol. IX, Philadelphia, Harper and Row, 1987. Pellock JM: Seizures. In: Zanga JR(ed): Pediatric Emergencies.
New York: Churchill Livingstone, 1986. Pellock JM: Forward for the Parents of Children With Epilepsy.
In: Berman RG: Learning About Epilepsy. Langham Pennsylvania: The Medicine Group,
1988. Pellock JM, Myer EC (eds): Neurologic Emergencies in Infancy and
Childhood. (Russian translation), Mockba: Russian Press, 1988. Pellock JM (guest ed.): Seizure Disorders. Pediatric Clin N Am,
36(2), 1989. Philadelphia: W.B. Saunders Pellock JM: Syndromes of Chronic Epilepsy in Children in Trimble
MR (ed): Resistant epilepsy; Its management and Prognosis. Chichester, J. Wiley
and Sons, 1989. Pellock JM: The Adolescent Female with Epilepsy. In: Trimble MR
(ed): Women and Epilepsy. John Wiley & Sons, LTD, London, 1991. Pellock JM: Rational Use of Valproate in Adults and Children In:
Levy RH, Penry JK (eds): Idiosyncratic Reactions to Valproate. Clinical Risk
Patterns and Mechanisms of Toxicity. Raven Press, New York, 1992. Pellock JM, Myer EC: Static Encephalopathy. In: Kaufman DM, Solomon
GE (eds): Pediatric Neurology for Child Psychiatrists. Baltimore: Williams &
Wilkins, 1992. Pellock JM: The Differential Diagnosis of Epilepsy: Non-Epileptic
Paroxysmal Disorders. In: Wyllie E (ed): The Treatment of Epilepsy: Principles
and Practice. Malvern, Pennsylvania, Lea & Febiger, 1992. Pellock JM, Johnson MH: Dandy-Walker Malformation. In: Lechtenberg
R (ed): Handbook of Cerebellar Disease. New York: Marcel Dekker, 1992. Dodson WE, Pellock JM (eds): Pediatric Epilepsy, Diagnosis and
Therapy. New York: Demos, 1993. Pellock JM, Pippenger CE: Adverse Effects of Antiepileptic Drugs.
In: Dodson WE, Pellock JM (eds): Pediatric Epilepsy, Diagnosis and Therapy.
New York: Demos, 1993. Pellock JM: Status Epilepticus. In: Dodson WE, Pellock JM (eds):
Pediatric Epilepsy, Diagnosis and Therapy. New York: Demos, 1993. Pellock JM, Myer ED (eds): Neurologic Emergencies in Infancy and
Childhood. (Portuguese translation), 1993. Pellock JM, Myer EC (eds): Neurologic Emergencies in Infancy and
Childhood. Second Edition, Butterworth Heinemann, Stoneham, MA, 1993. Pellock JM: Status Epilepticus. In: Pellock JM, Myer EC (eds):
Neurologic Emergencies in Infancy and Childhood. Second Edition, Butterworth
Heinemann, Stoneham, MA 1993. Pellock JM, The Use of New Antiepileptic Drugs in Children. In:
Trimble MR (ed): New Anticonvulsants. Advances in the Treatment of Epilepsy.
John Wiley & Sons, Ltd., London, 1994, pp. 127-143. Pellock JM, Coulter DA: Trimethadione. In: Levy RH, Mattson RH,
Meldrum BS (eds): Antiepileptic Drugs. 4th Edition, Raven Press, New York, 1995 Watemberg N, Pellock JM: Treatment and Prophylaxis of a First
Tonic-Clonic Seizure. In: Current Therapy in Neurologic Disease. 5th Edition.
Philadelphia: Mosby-Year Book, Inc., 1996. Pellock JM: The Differential Diagnosis of Epilepsy: Non-Epileptic
Paroxysmal Disorders. In: Wyllie E (ed): The Treatment of Epilepsy: Principles
and Practice. Second Edition. Malvern, Pennsylvania, Lea & Febiger. 1997:681-690. Pellock JM: New Antiepileptic Drugs: Age Related Efficacy. In:
Rowan AJ, Ramsay RE (eds): Seizures and Epilepsy in the Elderly. Boston: Butterworth-Heinemann;
1997:279-289. Schachter SC, Montouris GD, Pellock JM (eds): The Brainstorms
Family, Epilepsy on Our Terms. Lippincott - Raven, Philadelphia, 1997. Pellock JM: Epilepsy and Seizures in Children. In: Schachter SC,
Montouris GD, Pellock JM: The Brainstorms Family, Epilepsy on Our Terms. Lippincott-Raven,
Philadelphia, 1997. Pellock JM, DeLorenzo RJ: Status Epilepticus. In: Porter RJ and
Chadwick D (eds): The Epilepsies 2. Boston: Butterworth-Heinemann; 1997. Willmore LJ, Pellock JM: Chronic Monitoring Strategies. In: Engel
J, Pedley TA (eds) Epilepsy: A Comprehensive Textbook. Lippincott-Raven, 1997. Pellock JM: Drug Treatment in Children with Epilepsy. In: Engel
J, Pedley TA (eds) Epilepsy: A Comprehensive Textbook. Lippincott-Raven, New
York, 1997. Simon JL, DeLorenzo RJ, Pellock JM: Acute Morbidity and Mortality
of Status Epilepticus. In: Engel J, Pedley TA (eds): Epilepsy, A Comprehensive
Textbook. Lippincott-Raven, New York, 1997. Pellock JM: Treatment and Prophylaxis of a First Tonic-Clonic
Seizure. In: Kassirer JP, Greene HL (eds): Current Therapy in Internal Medicine.
4th Edition. Philadelphia: Mosby-Year Book, Inc., 1997. Rust RS, Pellock JM: Neonatal Seizures. Neurology Practice Guidelines
Lechtenberg/Schutta. New York: Marcel Dekker, Inc., 1997. Watemberg N, Pellock JM: First Tonic-Clonic Seizure in an Adult:
Treatment and Prophylaxis. Current Therapy in Adult Medicine Fourth Edition,
Kassirer and Greene (eds). St. Louis: Mosby-Year Book, Inc., 1997:1380-1384 Pellock JM: Pediatric Trials: Practical Issues. Special Populations
and Trial Design. In: French JA, Leppik IE, Dichter MA (eds): Advances in Neurology,
Volume 76, Antiepileptic Drug Development. Lippincott-Raven, Philadelphia, 1997:
167-171 Simon R, Pellock JM, DeLorenzo RJ: Acute Morbidity and Mortality
of Status Epilepticus. In: Engel J, Pedley TA (eds): Epilepsy: A Comprehensive
Textbook. Lippincott-Raven, Philadelphia. 1997:741-753. Boggs JG, Towne AR, DeLorenzo RJ, Pellock JM: Status Epilepticus.
In: Gilchrist JM (ed): Prognosis in Neurology. Butterworth-Heinemann, Boston,
1998:57-61 Pellock JM: Clinical Care and Dr. J. Kiffin Penry. In: Schachter
SC, Rowan AJ (eds): The Brainstorms Healer: Epilepsy in Our Experience. Lippincott-Raven,
Philadelphia. 1998. Pellock JM: Recurrent Seizures. In: Maria BL (ed): Current Management
in Child Neurology. Decker, Hamilton, London. 1999:148-155 Pellock JM: Acute Seizure Emergencies. In: Maria BL (ed): Current
Management in Child Neurology. Decker, Hamilton, London. 1999:289-295 Pellock JM: Status Epilepticus. In: Swaiman KF, Ashwal S (eds):
Pediatric Neurology: Principles and Practice, 3rd Edition. CV Mosby Co., 1999:683-691. Morton LD, Pellock JM: Treatment Options for Acute Seizure Care.
In: Mallarkey G, Palmer KJ (eds). Issues in Epilepsy, Adis International, 1999:29-41. Pellock JM: Use of the new antiepileptic drugs in paediatrics.
In: Pellock JM (ed). Broadening the spectrum of clinical uses of antiepileptic
drugs. Royal Society of Medicine, London, 2000. Pellock JM. Medical Treatment of focal epilepsies. In: Luders
HO (ed). Epilepsy: Comprehensive Review and Case Discussions. Martin Dunitz,
London, 2001. DeVivo DC, Percy AK, Chiriboga CA, deVeber G, Dobyns WB, Iannaccone
SE, Mandelbaum DE, Nass R, Paneth N, Pellock JM, Roach ES, Rutledge SL, Singer
HS, Zupanc ML. Pediatric Neurology. In: Continuum: Lifelong Learning in Neurology
6(4):August 2000. Parts A&B. Pellock JM: The Differential Diagnosis of Epilepsy: Other Non-Epileptic
Paroxysmal Disorders. In: Wyllie E (ed): The Treatment of Epilepsy: Principles
and Practice. Third Edition, 2001. Pellock JM, Dodson WE, and Bourgeois B (eds): Pediatric Epilepsy,
Diagnosis and Therapy, 2nd Edition. New York: Demos, 2001. Leszczyzyn DJ, Pellock JM. Status Epilepticus. In: Pellock, JM,
Dodson WE, Bourgeois B (eds). Pediatric Epilepsy, Diagnosis and Treatment. 2nd
edition. New York: Demos, 2001. Pellock JM and Duchowny M: Partial Seizures. In: Dr. Maria (ed):
Current Management in Child Neurology, Second Edition, in press, 2001. Pellock JM. First Choice Antiepileptic Drugs. In: Dr. Maria (ed):
Current Management in Child Neurology, Second Edition, in press, 2001. Abstracts, Letters, Reviews, etc. Rhee S, Margolin M, Pellock JM: Palatal myoclonus and diphenylhydantoin
therapy. N Engl J Med 1974;290:1088. [Letter] Pellock JM: Epilepsy Collier's Encyclopedia, MacMillian Company,
New York, 1976. [Review] Pellock JM, Berenberg R, DiMauro S, et al: Lumping or splitting?
"Ophthalmoplegia plus" or Kearns-Sayre syndrome? Arch Neurol 1976;33:3889. [Abstract] Britton DE, Pellock JM, Eiben RM: Acute hemiplegia of childhood.
Lactate-pyruvate acidemia and mitochondrial disorder. Ann Neurol 1977;2:265.
[Abstract] Pellock JM, McDonald BM, Kleinman PK, Wilson: Hypertension in
acute neurological disease in childhood. Develop Med Child Neurol 1978;10:832-3.
[Letter] Pellock JM: Reyes Syndrome. Collier's Encyclopedia, MacMillian
Company, New York, 1979. [Review] Pellock JM, Chan JMC: Neurological complications of renal failure
and dialysis in children. Clinical Res 1979;27:823A.[Abstract] Garnett WR, Carter BL, Pellock JM: Bioavailability of phenytoin
administered with antacids. Therap Drug Monit 1979;1:435-7. [Letter] Garnett WR, Carter BL, Pellock JM: Effect of calcium and antacids
on phenytoin bioavailability. Arch Neurol 1980;37:467. [Abstract] Pellock JM: Hyperactivity. Collier's Encyclopedia, MacMillian
Company, New York, 1980. [Review] Pellock JM, Flannery DB, Mamunes P, Robertson LW: The fetal primidone
syndrome. Ann Neurol 1982;12:209. [Abstract] Pellock JM: Hyperactivity. Merit's Encyclopedia, New York: MacMillian
Company, 1982. [Review] Pellock JM: Comments on EEG use in febrile seizures. In: Nelson
KB, Ellenberg JH (eds.) Febrile Seizures . Raven Press, New York, 1982. Garnett WR, March CL, Tarasidis C, Pellock JM: Assessment of total
and free valproic acid levels in serum and plasma in children. Ann Neurol 1983;14:369.
[Abstract] Garnett WR, Pugh CB, Pellock JM: Validation and chronic usefulness
of a single dose prediction model to forecast the total and free steady-state
concentrations of valproic acid in epileptic patients. Epilepsia 1984;25:643.
[Abstract] Tarasidas G, Garnett WR, Kline BJ, Pellock JM: The effect of tube
type, storage time, and temperature on the total and free concentration of valproic
acid. Epilepsia 1984;25:642-3. [Abstract] Pellock JM, Carzo CG, Garnett WR: Carbamazepine in children: Clinical
and laboratory adverse effects. Ann Neurol 1984;16. [Abstract] Pellock JM, Carzo CG, Garnett WR: Carbamazepine in children: Efficacy
and adverse effects. Epilepsia 1984;25:661-2. [Abstract] Hubbell JP, Garnett WR, Pellock JM, et al: Pharmacokinetics of
Lamotrigine (BW-430C) in epileptic patients. Epilepsia 1985;26:537. [Abstract] Pellock JM, Garnett WR, Fitzgerald BE, Valakas T, Lai A, Cloutier
G: Acute dose of tolerance of Lamotrigine (BW-430C) in epileptic patients. Epilepsia
1985;26:536-7. [Abstract] Fitzsimmons WE, Garnett WR, Comstock TJ, Pellock JM: Single dose
comparison of the relative bioavailability of phenytoin suspension and extended
capsules. Epilepsia 1985;26:536. [Abstract] Maas B, Garnett WR, Comstock TJ, Pellock JM: Comparison of the
relative bioavailability pharmacokinetics of carbamazepine tablets and chewable
and tablet formulations. Ann Neurol 1985;18:379. [Abstract] Pellock JM, Garnett WR, Ramsey RE, et al: Chronic dose tolerance
of lamotrigine in epileptic patients. Epilepsia 1986;27:647. [Abstract] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Pellock JM,
et al: Effect of two administration schedule of an enteral nutrient formula
#ENF on phenytoin bioavailability. Epilepsia 1986;27:593. [Abstract] Lai A, Wargin WA, Garnett WR, Pellock JM et al: Pharmacokinetics
of Lamotrigine in epileptic patients following multiple oral dosing. Epilepsia
1986;27:647-8. [Abstract] Pellock JM: Review of Pedley TA, Meldrum BS (eds.) Recent advances
in epilepsy-2. New York, Churchill Livingstone, 1985, Epilepsia 1986;27:93.
[Book Review] Maas B, Garnett WR, Pellock JM: Adverse effects associated with
long-term use of valproic acid in children. Ann Neurol 1986;20:429.[Abstract] Pellock JM: Treating epilepsy. In: Health and Medical Horizons.
MacMillian, 198 |